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DISCRIMINATIVE STIMULUS EFFECTS OF 3,4-METHYLENEDIOXYPYROVALERONE AND
4-METHYLMETHCATHINONE

Michael D. Berquist II, Ph.D.
Western Michigan University, 2016
Recent escalation in the popularity of recreational synthetic cathinone (“bath salts”) use has
prompted numerous scientific investigations of the neurochemical and behavioral effects of
3,4-methylenedioxypyrovalerone (MDPV) and 4-methylmethcathinone (4-MMC), two of the more
common chemical constituents of these illicit “bath salts”. Previous neurochemical and
electrophysiological studies have revealed that MDPV functions as a blocker, and 4-MMC as a substrate, at
monoamine transporters, and both produce transient increases in extracellular monoamines. In addition,
previous research has demonstrated that MDPV and 4-MMC support self-administration in nonhuman
experimental subjects, and their rewarding effects are observed when paired with contextual cues in
nonhuman models of conditioned place preference. Comparatively fewer studies have characterized the
discriminative stimulus effects of these drugs using drug discrimination methods. The drug discrimination
paradigm is an in vivo drug-detection assay with high predictive validity. To further characterize the
discriminative stimulus effects of these synthetic cathinones, the current study trained 16 male
Sprague-Dawley rats to discriminate either 0.3 mg/kg MDPV (N = 8) or 1.0 mg/kg 4-MMC (N = 8) from
saline.
Once the rats met discrimination acquisition criteria, substitution tests were conducted with
compounds that function as dopamine releasers (d-amphetamine, (+)-methamphetamine), monoamine
transporter inhibitors (MDPV, (-)-cocaine), monoamine transporter releasers (4-MMC, MDMA), a
serotonin releaser ((+)-fenfluramine), and an indoleamine hallucinogen (lysergic acid diethylamide,
(+)-LSD). Discriminative stimulus control was established in ~35 and ~37 training sessions in the 0.3

mg/kg MDPV group and 1.0 mg/kg 4-MMC group, respectively. In the 0.3 mg/kg MDPV training group,
the aforementioned dopamine releasers, monoamine transporter inhibitors, and (+)-fenfluramine produced
full substitution, whereas the monoamine transporter releasers and (+)-LSD failed to fully substitute and
produced statistical reductions in response rate. In the 1.0 mg/kg 4-MMC training group, all drugs except
(+)-LSD and (+)-fenfluramine produced full substitution. Overall, these findings are consistent with human
user reports indicating that MDPV and 4-MMC produce interoceptive stimulus effects that are comparable
to prototypical drugs of abuse, such as cocaine and MDMA. Future studies with receptor-selective
antagonists would be especially valuable to further investigate the neurochemical actions contributing to
the discriminative stimulus effects produced by these substances.
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INTRODUCTION
Drug Use
The consumption of psychoactive substances is a pervasive feature of the human experience.
Throughout history, communities worldwide have eaten plants, inhaled vapors, and drank concoctions that
produced psychoactive effects. Users consumed many of these substances for particular occasions, such as
during spiritual ceremonies (e.g., some evidence suggests that Native Americans may have known of
peyote’s psychoactive properties for over 5700 years; El-Seedi, De Smet, Beck, Possnert, & Bruhn, 2005)
or during divination and healing activities (e.g., coca leaves have a rich history in Peruvian cultures;
Valdez, Taboada, & Valdez, 2015). During these occasions, drug effects could have functioned as
establishing operations for subsequent behavior (e.g., increasing the reinforcing value of reaching a
destination during a hike), or elicited responses that may have been rewarding in their own right to users
(e.g., altered perceptual experiences). Despite whatever the behavioral function(s) of the drug may have
been, it is clear that many of these communities prospered in their ecological niches and some continue to
thrive today regardless of the purity and amount of drug at their disposal.
A different portrayal of drug consumption exists in mainstream, present day American society. In
the worst cases, the use and distribution of drugs highlights major media reports with stories of illegal drug
trafficking and human tragedies. Docudramatic vignettes are often presented to illustrate how drug
consumption had become so severe for users that their lives had all but shattered. Somewhat less ominous,
and much less sensationalized, are the millions of Americans who begin each day with a few cups of a
caffeinated beverage or a nicotine-packed product. For many of these habitual users, the coffee or cigarette
in the morning is commonplace and they can continue drug use without receiving social condemnation (or
sympathy). Therefore, it seems a division exists between those who compulsively use drugs to excess, or in
an otherwise harmful manner, and those whose use does not disrupt daily functioning to any appreciable
extent. A goal of substance use research is to identify the environmental situations in which a person is
likely to misuse a drug and form neurochemical and behavioral dependencies.
Characteristics of certain drugs—some defined functionally through interactions with
biological/behavioral systems and others socially through cultural norms—may pose greater risks to users’
welfare. Such characteristics may include a drug’s dose-dependent, unconditioned physiological effects
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(e.g., endorphin-releasing effects in the central nervous system), its legal status or social acceptance, and its
behavioral function(s) for the user (e.g., ethyl alcohol can produce increases in sociability among users). It
is noteworthy to emphasize that some individuals often consider drugs as inherently “good” or “bad”,
although it is likely that many of these assessments are due to socio-political factors or correlations
between their use and some adverse event, rather than scientific evidence demonstrating that a drug
produces positive or untoward effects. For example, in 2014, 22.2 million people were reported to use
marijuana for nonmedical purposes (Center for Behavioral Health Statistics and Quality, 2015). This figure
may seem alarming, but it is presently unclear whether marijuana use is strongly associated with relatively
high levels of social or personal harm. Taylor et al. (2012) surveyed 292 clinical experts across Scotland to
evaluate the relative harm to self and others of 19 commonly used drugs. These authors found that heroin,
crack cocaine, crystal methamphetamine, alcohol, and cocaine were ranked as the top five, most harmful
drugs in a combined personal-social harm measure. Contrariwise, lysergic acid diethylamide (LSD),
Ecstasy/MDTA, methylphenidate/Ritalin, psilocybin (“magic mushrooms”), and cannabis were ranked as
the five least harmful drugs. In addition, the clinical experts ranked nicotine as the seventh most harmful
drug on this list. Although these now dated findings may only generalize to Scottish individuals (also see
Nutt, King, & Phillips, 2010), it is possible (though, to the present author’s knowledge undetermined) that
American clinical experts would report similar relative indices of harm for these drugs in the United States.
Indeed, during the time of this writing, cannabis and its major psychoactive constituent,
Δ9-tetrahydrocannibol, is becoming legal for recreational possession and use in some states of the U.S.;
although, according to U.S. federal regulations, the drug is illegal to use or possess.
In contrast to the aforementioned use of marijuana in the United States in 2014, daily consumption
of a caffeinated beverage was as high as 85% of the total U.S. population (Mitchell, Knight, Hockenberry,
Teplansky, & Hartman, 2014). Perhaps in the future a similar percentage of the U.S. population will be
consuming marijuana or other drugs that are currently labeled as illicit. Historical accounts have
demonstrated that the popularity of some drugs wax and wane over time and cultures, leading to social
acceptance for some substances (e.g., cannabis, nicotine, ethyl alcohol), but not others (e.g., heroin,
methamphetamine, LSD). Certain drugs in one particular chemical class, the synthetic cathinones (referred
to as “bath salts”), are currently considered an international public concern because recent media, legal, and
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toxicology reports have identified associations between consumption of these drugs and adverse events
(e.g., death, crimes). Previous experimental reports have revealed that particular substances in the class of
synthetic cathinones function as potent reinforcers for appetitive responses and possess relatively high
abuse potential as inferred using common methods in preclinical research (see below). More experimental
research on these substances is necessary to further characterize their behavioral effects. The research
included herein provides insight into the possible interoceptive effects produced by two synthetic
cathinones that may assist in informing individuals in the public, private, and government sectors of the
drugs’ effects on behavior.
Consistent with the foregoing introduction, it remains undetermined if the next emergent class of
drugs will replace the consumption of the synthetic cathinones, whether societies will become more liberal
concerning synthetic cathinone use, or, if these substances remain labeled illicit, perhaps their popularity
will resurge in the future. In any event, rigorous experimental assessments of these drugs may prove
valuable for future efforts devoted toward limiting, reducing, or simply knowing the effects produced
following their consumption. The present dissertation includes an investigation of the discriminative
stimulus effects of two synthetic cathinones, 4-methylmethcathinone (4-MMC) and
3,4-methylenedioxypyrovalerone (MDPV), using drug discrimination procedures in male Sprague-Dawley
rats. Before discussing an overview of the synthetic cathinones, a brief review of the parent compound,
cathinone, is presented.
Cathinone
Use, prevalence, and pharmacokinetics. Cathinone [(S)-(-)-α-aminopropiophenone] is an
alkaloid found within the leaves of the Catha edulis Forsk shrub. The plant is native to regions of Africa
and the Arabian Peninsula where for centuries indigenous communities have consumed its leaves as an
“energizer” for work and climbing activities (Kennedy, Teague, Rokaw, & Cooney, 1983), during social
settings (Kalix, 1988), and to experience psychostimulant-like effects (for review, Pantelis, Hindler, &
Taylor, 1989). Other names for Catha edulis Forsk, each of which is region-specific, include khat (most
common), qat, chat, mirra, or qaad/jaad (Alem, Kebede, & Kullgren, 1999).
Khat use is common among individuals from Yemen and other East African cultures (European
Monitoring Centre for Drugs and Drug Addiction [EMCDDA], 2015a). Khat users commonly chew the
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plant’s leaves, a process which extracts ~90% of available cathinone from their contents (Toennes &
Kauert, 2002; Toennes, Harder, Schramm, Niess, & Kauert, 2003); although, previous reports have
indicated that dried khat leaves are sometimes brewed in teas or smoked (Hodgkinson, 1962; Giannini,
Miller, & Turner 1992). While chewing the plant, cathinone is absorbed through the user’s buccal mucosa
and gastrointestinal tracts, and it reaches peak plasma concentrations about two hours post-consumption
(Toennes, Harder, Schramm, Niess, & Kauert, 2003). Metabolism of cathinone to norephedrine (or
phenylpropanolamine) and norpseudoephedrine (or cathine) occurs following ingestion (Brenneisen,
Geisshüsler, & Schorno, 1986) and cathinone can be detected in urine for 22-26 hours post-consumption
(Toennes & Kauert, 2002). For an extensive review of khat’s chemical constituents and pharmacokinetics,
see Feyissa and Kelly (2008).
Legal status. Despite khat’s (and cathinone’s) popularity among recreational users in Eastern
Africa and Arabian regions, several countries have created legal regulations to control its use and
distribution. Indeed, cathinone was listed as Schedule I at the United Nations Convention on Psychotropic
Substances (United Nations Office on Drugs and Crime, 2016). In addition, the European Union has
classified khat as a controlled substance in 15 of its 27 member countries (EMCDDA, 2011), and the
United States placed cathinone on the list of controlled substances in 1993 (Drug Enforcement Agency
(DEA), 1993). In Canada, cathinone is a Schedule III substance under the 1996 Controlled Drugs and
Substances Act (Government of Canada, 2016). Although khat use and possession became illegal in the
U.S. in 1993, law enforcement agencies have seized large quantities of the plant in the years following. For
example, according to the Federal-wide Drug Seizure System, legal authorities seized 89,669 kilograms of
khat in 2010 (DEA, 2013). Further, the DEA (2013) reported that distributors from Africa and the Middle
East were responsible for transporting khat into the United States. It is noteworthy that
synthetically-derived formulations of cathinone (viz. synthetic cathinones) may have replaced khat
availability among the illicit drug markets (for review, Nichols, Khondkar, & Gibbons, 2015).
Neurochemical profile. Comprehensive characterization of a drug’s neurochemical effects serves
as a useful starting point for understanding how and why it affects behavior. One fruitful area of research
devoted toward investigating how a drug’s molecular structure affects its pharmacological activity is
through structure-activity relationship studies (for review, Glennon and Young, 2011a). Essentially, some
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chemical property of a drug is altered or isolated (e.g., optical rotation, chirality) and its pharmacological
activity is subsequently assessed. Among the many sub-areas within the study of structure-activity
relationships, investigations of drug enantiomers and optical isomers (viz. stereochemistry) are especially
valuable. For example, Dal Cason (unpublished observations, cited in Sparago et al. 1996) reported that the
sinister enantiomer (usually denoted by an S preceding a drug’s name1) of methcathinone, a cathinone
derivative, was more commonly found in the illicit drug market than the R enantiomer. Such information
can be useful for determining whether to evaluate the effects a drug enantiomer or a racemic drug using
experimental methods, and, as in the foregoing case of methcathinone, useful for distinguishing if an
enantiomer is more potent at producing one effect (e.g., locomotor stimulant effects) over another (e.g.,
neurotoxicity). In any case, evaluations of a drug’s structure-activity relationships has been and continues
to be an active area in drug use research.
Previous studies have assessed the neurochemical and behavioral effects of racemic cathinone or
cathinone enantiomers using established methods in preclinical research. For example, Glennon and
Liebowitz (1982) demonstrated that the S(-)-cathinone enantiomer possesses twice the affinity as racemic
(±)-cathinone for serotonin receptors (measured using pA2 values obtained from Schild plots; see
Arunlakshana & Schild, 1959). These receptor affinity values were measured using rat fundus preparations.
The authors of that study were among the first to evaluate the structure-activity relationship of a cathinone
enantiomer. In a later study, Rothman et al. 2003 demonstrated that S(-)-cathinone has relatively potent
releasing effects of norepinephrine and dopamine, as measured in cloned human substrates (see cathinone
as test agent at Psychoactive Drug Screening Program: Ki Database, n.d.). The norepinephrine- and
dopamine-releasing effects of S(-)-cathinone are similar to d-amphetamine (e.g., Rothman et al. 2001).
Overall, the foregoing studies have demonstrated the relative potency of a cathinone enantiomer compared
to racemic cathinone (Glennon & Liebowitz, 1982) and the neurochemical targets to which S(-)-cathinone
produces potent, monoamine releasing effects (Rothman et al. 2003). These results are in part valuable for
determining the neurochemical bases of cathinone’s behavioral effects.

1

A racemic drug (or racemate) consists of equal amounts of left- and right-handed enantiomers and is
sometimes abbreviated as (±) or (SR), which precedes the drug’s name. A rectus enantiomer is often
denoted by R preceding the drug name.
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In addition to the aforementioned in vitro experiments that have evaluated cathinone’s
neurochemical effects, previous studies have included ex vivo techniques as well. For example,
Fleckenstein et al. (1999) examined the extent to which cathinone would prevent (i.e., compete with)
[3H]dopamine and [3H]serotonin uptake at dopamine (DAT) and serotonin transporters (SERT) in rat
striatal synaptosomes, respectively. Groups of rats had previously received a single injection or multiple
injections (sc) (i.e., four injections spaced two hours apart) of 40 mg/kg cathinone and were decapitated one
hour after the final injection. Compared to saline-treated rats, single or multiple injections of 40 mg/kg
cathinone produced statistically significant reductions in dopamine uptake at DAT, and multiple injections
produced significant reductions in serotonin uptake at SERT. Overall, these data demonstrate that 40 mg/kg
cathinone reduces the transporter functions of DAT, and, in a dosing-specific manner, SERT. Further, in
discussing the singular effect of cathinone (and other psychoactive substances not mentioned here) on
SERT functioning observed only after the multiple injection procedure, Fleckenstein et al. suggested that in
vitro characterizations (or single drug administrations) may not accurately portray a drug’s effects when
subjects are repeatedly exposed to drugs in vivo.
The foregoing studies illustrate how different approaches can be used to determine a drug’s
neurochemical effects. Though beyond the scope of the present document to further discuss cathinone’s
neurochemical actions (for review, Feyissa & Kelly, 2008), it is clear that experiments including in vitro
and ex vivo techniques can serve as useful starting points for subsequent investigations. Moreover, such
techniques make available comparisons of drugs with imperfectly known neurochemical effects, such as
cathinone during the time at which these studies were conducted, to prototypical psychoactive drugs, such
as amphetamine.
Psychopharmacology of cathinone. Researchers have extensively investigated the bio-behavioral
effects of cathinone using several measures commonly used in human psychopharmacology research. For
example, Brenneisen, Fisch, Koelbing, Geisshüsler, and Kalix (1990) observed in human volunteers that
cathinone consumption produces increases in blood pressure, heart rate, psychostimulant-like, and
euphorigenic effects—some of which are consistent with the habitual users’ reports mentioned in the
introduction of the present document. Previous studies have reported that compared to non-khat users,
habitual khat users display irregular diurnal salivary cortisol levels and blunted blood pressure levels in
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response to mistakes made on a mental arithmetic task (al’Absi et al., 2013), poorer accuracy and increased
reaction times in working memory and task-switching procedures, respectively (Colzato, Ruiz, van den
Wildenberg, & Hommel, 2011), and disrupted sleep (Nakajima et al., 2014). Amid these findings, Numan
(2004) failed to observe high incidents of psychological morbidity in a sample of 800 Yemini adults (age
range: 15-76) of which over 80% of males and 40% of females indicated at least a single episode of khat
use in their lifetimes. Therefore, similar to the untoward effects produced by the consumption of other
illicit drugs, khat’s adverse effects are likely dependent on interactions with other environmental and
biological factors present during the time of consumption.
Reports of cathinone’s effects on nonhuman animal behavior using common procedures in
behavioral pharmacology research are also widespread. Select studies highlighting the behavioral effects of
cathinone will now be presented for exposition. Gugelmann, von Allmen, Brenneisen, and Porzig (1985)
compared the effects of (+)- and (-)-cathinone optical isomers2 to (+)-amphetamine on locomotor activity in
rats. Among the doses tested, 3.0 and 6.0 mg/kg (-)-cathinone produced greater locomotor activity than
(+)-cathinone, and greater levels than 6.0 mg/kg (+)-amphetamine. Johanson and Schuster (1981)
demonstrated in rhesus monkeys that dl-cathinone and l-cathinone decreases food-reinforced responding
and maintains self-administration. In a later study, Woolverton and Johanson (1984) reported that in rhesus
monkeys trained to self-administer cocaine or dl-cathinone under a drug-drug, discrete-trials choice
procedure, increasing doses of cocaine were necessary to shift a preference to cocaine from dl-cathinone as
the dose of dl-cathinone increased. Moreover, these authors found that the drug-drug choice results
obtained from the foregoing procedure revealed that the reinforcing efficacies of dl-cathinone and cocaine
were comparable.
Of particular relevance to the experiment described herein, previous reports have also investigated
cathinone’s discriminative stimulus effects using drug discrimination procedures. Drug discrimination
procedures typically involve training experimental subjects (usually rodents) to discriminate between a
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In the context of drug molecules, “optical isomers” refers to the direction in which a drug rotates when
exposed to polarized light. If the isomer rotates clockwise in the direction of the oncoming light stimulus,
this is referred to as dextrorotary (also referred to as d or (+) preceding a drug name). Contrariwise, if the
isomer rotates counter-clockwise in the direction of the oncoming light stimulus, this is referred to as
levorotary (also referred to as l or (-) preceding a drug name). Racemic mixtures of optical isomers can be
referred to as dl, (±), or “nothing” preceding a drug name.
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dose of a psychoactive substance (e.g., injection of 10 mg/kg cocaine; the “training drug”) from its absence
(e.g., injection of saline). Specifically, subjects are differentially reinforced (e.g., using a food pellet as a
reinforcer) to emit one response in the presence of the drug (e.g., lever press on left lever in operant
conditioning chamber) and emit a different response in the absence of the drug (e.g., right lever press).
Once subjects reach some specified level of discrimination accuracy (e.g., >80% condition-appropriate
responding for 8 out of 10 consecutive training sessions), then other doses of the training drug can be tested
for substitution (i.e., testing whether the interoceptive cue produced by different doses of the training drug
or doses of a different drug “substitute” for the training drug cue). Substitution generally falls into three
qualitative categories: no substitution, partial substitution, or full substitution. No substitution is generally
considered ≤20% drug-lever selection, partial substitution is >20% but <80% drug-lever selection, and full
substitution is ≥80% drug-lever selection. Thus, for example, if a test drug produces full substitution, then
it is declared that the test drug and training drug produce similar discriminative stimulus effects. See below
for additional information regarding the drug discrimination paradigm.
Schechter, Rosecrans, and Glennon (1984) reported the first known experiment to train
ARS/Sprague-Dawley rats to discriminate (±)-cathinone (0.6 mg/kg) from saline. All rats acquired the
discrimination (i.e., met the authors’ criterion of 8 out of 10 consecutive sessions of condition-appropriate
responding) within 30 sessions. Injections of 0.8 and 0.4 mg/kg d-amphetamine equipotently (cathinone
ED50 value: 0.21 mg/kg; d-amphetamine ED50 value: 0.24 mg/kg) produced full substitution in the 0.6
mg/kg cathinone-trained rats, suggesting common discriminative stimulus properties between the two
drugs. In contrast, apomorphine (0.16, 0.24, and 0.32 mg/kg) failed to produce full substitution. Schechter,
Rosecrans, and Glennon (1984) concluded that the similarity in potency and responding between
(±)-cathinone and d-amphetamine suggests that the drugs may produce their discriminative stimulus effects
through a common pharmacological mechanism of action.
In a later study, Goudie, Atkinson, and West (1986) investigated whether doses of several
centrally-acting stimulants (i.e., d-amphetamine, cocaine, methylphenidate, pipradrol, and cathine) would
generalize in rats trained to discriminate 2.0 mg/kg dl-cathinone from saline. The median sessions required
to reach the discrimination criterion (i.e., 10 consecutive sessions of responding on the
injection-appropriate lever prior to the delivery of the first reinforcer) was 21 sessions. All of the foregoing
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stimulants produced full substitution (i.e, in a dose-dependent manner, suggesting that these stimulants
share common centrally-acting interoceptive effects. Moreover, the sympathomimetic,
p-hydroxyamphetamine, failed to fully substitute in the rats, indicating that 2.0 mg/kg cathinone appears to
produce its interoceptive effects through a centrally-mediated cue. Stimulus blockade tests with a D2
receptor antagonist, haloperidol, were also performed in this experiment. Pre-treatment with 0.25 or 0.3
mg/kg haloperidol in conjunction with 2.0 mg/kg cathinone reduced percent cathinone-lever selection from
85.7% (i.e., the mean percent selection value of 2.0 mg/kg cathinone) to 66.7% and 50%, respectively.
Because complete blockade was not produced by the largest dose of haloperidol tested (0.3 mg/kg), other
receptor actions are likely involved in mediating the 2.0 mg/kg cathinone cue (Goudie, Atkinson, & West,
1986).
To further investigate the discriminative stimulus effects of cathinone enantiomers, previous
studies have evaluated whether these compounds generalize in groups of rats trained to discriminate a
hallucinogen or a centrally-acting stimulant from saline. For example, Glennon (1986) investigated the
discriminative stimulus effects of (±)-, S(-), and R(+)-cathinone in rats trained to discriminate 1.0 mg/kg
(±)-DOM (2,5-dimethoxy-4-methylanalog) or 1.0 mg/kg (+)-amphetamine sulfate from saline. The results
of this study revealed that rats injected with doses of the cathinone enantiomers (0.2-20 mg/kg) failed to
show substitution in DOM-trained rats, but all enantiomers produced full generalization in the
amphetamine-trained rats (ED50 values of cathinone enantiomers expressed in mg/kg: (±)- 0.72, S(-) 0.34,
and R(-)4.41). Based on these obtained ED50 values, Glennon (1986) concluded that the S(-) cathinone
enantiomer is approximately ten times more potent as the R(-) enantiomer in producing amphetamine-lever
responding (i.e., amphetamine-like interoceptive effects).
A later study by Young and Glennon (1998) evaluated whether racemic cathinone and the
S-cathinone enantiomer would substitute in rats trained to discriminate the cathinone derivative
methcathinone from saline. In this study, rats were trained to discriminate 0.5 mg/kg S(-)-methcathinone
from saline under a variable-interval 15-sec schedule of sweetened milk reinforcement. Doses of
(±)-cathinone (0.25, 0.50, 0.85, and 1.0 mg/kg) and S(-)-cathinone (0.125, 0.20, 0.25, and 0.50 mg/kg) were
among the compounds tested for stimulus substitution. Racemic cathinone and S-cathinone produced full
substitution in the S(-)-methcathinone-trained rats, and the ED50 value of the S(-)-cathinone isomer (0.19
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mg/kg) was reportedly lower than the ED50 value of (±)-cathinone (0.41 mg/kg), although this difference
was not statistically significant (i.e., the associated 95% confidence intervals did not overlap). Based on
these findings, Glennon and Young (1998) concluded that the S(-)-methcathinone enantiomer may produce
its discriminative stimulus effects through dopaminergic mechanisms, similar to the effects of cathinone.
The foregoing drug discrimination experiments using racemic cathinone or a cathinone enantiomer
as the training drug, or testing whether cathinone enantiomers would substitute in subjects trained on some
other centrally-acting compound, supports the use of drug discrimination methods to investigate
quantitative and qualitative effects of cathinone in vivo. Though beyond the scope of the present document
to describe every drug discrimination study involving cathinone, the foregoing studies demonstrated that
drugs that enhance dopamine release or otherwise increase extracellular dopamine levels (e.g.,
amphetamine, cocaine, methylphenidate) produce discriminative stimulus effects that are comparable to
cathinone (e.g., Schechter, Rosecrans, & Glennon,1984; Goudie, Atkinson, & West, 1986), and that
stimulation of the D2 receptor in particular mediates some aspect of cathinone’s interoceptive effects
(Goudie, Atkinson, & West, 1986). Contrariwise, drugs that stimulate serotonin receptors, such as DOM,
do not appear to produce discriminative stimulus effects that are similar to cathinone (e.g., Glennon, 1986).
The foregoing summary of the behavioral and neurochemical effects of cathinone demonstrates
the utility of experimentation in preclinical research. At the time the cathinone research was conducted,
investigations of the abuse liability and pharmacological effects of this drug was a socially-relevant
endeavor. Pertinent to the experiment planned herein, the discussion will now turn to synthetic analogues of
cathinone and the variety of experimental procedures in which they have been tested.
Synthetic Cathinones
Description, use, prevalence. Recent research interests in studying the behavioral and
neurochemical effects of substances within the aforementioned class of drugs known as the “synthetic
cathinones” (“bath salts”, “plant food”) are extensive. These drugs, as their class label implies, derive from
the constituent β-ketoamphetamine structure of cathinone. Some synthetic cathinones (i.e., β-ketos) are
used for medicinal purposes, such as diethylpropion (Tenuate®; produces anorexigenic effects, used to
treat obesity) and bupropion (Wellbutrin®; used as antidepressant and for smoking cessation). Among the
illicitly-labeled synthetic cathinones are 3,4-methylenedioxypyrovalerone (MDPV),
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4-methylmethcathinone (4-MMC, mephedrone), methcathinone (epedrone), methylone (βk-MDMA,
3,4-methylenedioxy-N-methylcathinone), methedrone (βk-PMMA, 4-methoxymethcathinone), and
α-pyrrolidinopropiophenone (EMCDDA, 2015b). It is noteworthy that there are other derivatives in
addition to those mentioned above, some of which are used medicinally and others that are labeled illicit
(see EMCDDA, 2015b).
According to the UNODC World Drug Report (2015), synthetic cathinones were the third fastest
growing (15 percent growth) new psychoactive substances worldwide in 2014 (third to synthetic
cannabinoids at 39 percent and phenethylamines at 18 percent). Common routes of administration among
synthetic cathinone users include swallowing, insufflation, inhalation, or injection (National Institute on
Drug Abuse, 2016). According to Erowid (2015a;b), oral doses of MDPV range from 2-25 mg and 4-MMC
range 15–300+ mg. A recent study revealed that in a sample of 145 4-MMC users in Sweden, 84.4%
insufflated and 11% injected, and those who injected used 4-MMC more frequently and at higher doses
(Kapitány-Fövény et al., 2015). In this same sample, the injector sub-group also comprised 37.5% opiate
users, suggesting that individuals who inject synthetic cathinones are likely to consume other drugs that are
delivered via similar drug administration routes. Further research is necessary to identify if this is an
ecologically-relevant issue among synthetic cathinone users.
Toxicities following the consumption of synthetic cathinones were well publicized by widespread
media attention in the early 2010s. Previous media reports have documented cases of violent and bizarre
behaviors, and death (e.g., Whitney, 2011; Campbell, 2012; “Police: Man on”, 2013). Due in part to these
reports, the Drug Enforcement Agency (DEA, 2011) added MDPV, 4-MMC, and methylone to the
Schedule I list of controlled substances on October 21, 2011. Moreover, an additional 10 bath salt
constituents were labeled as Schedule I March 7, 2014 (DEA, 2014). Despite these legal ramifications,
previous reports suggest that synthetic cathinone users may have continued to acquire these substances
using the Internet or other covert tactics (e.g., Schifano et al., 2011; for review, Vardakou, Pistos, &
Spiliopoulou, 2011). In 2011, consumption of synthetic cathinones accounted for 22,904 emergency room
visits and over 50% (~11,987 of cases) of the visits involved bath salts consumed in combination with other
drugs (The DAWN report, 2013). Other sources indicate that from January 1, 2016, to May 31, 2016, 166
human exposures to bath salts were reported to poison control centers in the U.S. (American Association of
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Poison Control Centers, n.d.), which included incidents of seizures, violent behavior, and hallucinations.
Further, the DEA (2011) revealed in 2011 that law enforcement agencies most commonly encountered two
constituents, MDPV and 4-MMC. As such, researchers have devoted considerable attention to the
neurochemical and behavioral effects of MDPV and 4-MMC.
Previous Research on MDPV and 4-MMC
The current literature corpus on MDPV and 4-MMC includes a broad range of research findings.
Researchers have evaluated the neurochemical and behavioral effects of MDPV and 4-MMC using a
variety of experimental methods commonly used in preclinical substance abuse research. Several of the
research findings are presented below for exposition.
Electrophysiological and neurochemical effects. Recent electrophysiological reports (Cameron,
Kolanos, Solis, Glennon, & De Felice, 2013; Cameron, Kolanos, Vekariya, De Felice, & Glennon, 2013)
demonstrated that MDPV produces an outward hyperpolarizing current at the human dopamine transporter
(hDAT), similar to the effects of cocaine. In addition to possessing a strong binding affinity to DAT (e.g.,
Simmler et al., 2013), studies have revealed that MDPV also possesses relatively strong binding affinity for
the norepinephrine transporter (NET) (Simmler et al., 2013), but exerts comparatively weaker effects (i.e.,
less binding affinity) on serotonin transporter (SERT) reuptake (Baumann et al., 2013a; Simmler et al.,
2013; Eshleman, Wolfrum, Hatfield, Johnson, Murphy, & Janowsky, 2013). Moreover, MDPV functions as
an inhibitor at hDAT and NET in vitro and it produces dose-dependent increases in extracellular dopamine
in rat nucleus accumbens in vivo (Baumann et al., 2013). In a recent study, Kolanos et al. (2015)
demonstrated that S(+)-MDPV was more potent than racemic MDPV or R(-)-MDPV in blocking DAT and
NET functioning, however no differences were observed among the isomers in inhibiting SERT
functioning.
Contrary to the foregoing effects of MDPV at hDAT, 4-MMC produces an inward depolarizing
current at hDAT (Cameron, Kolanos, Solis, Glennon, & De Felice, 2013; Cameron, Kolanos, Vekariya, De
Felice, & Glennon, 2013), similar to the effects of methamphetamine. Current research has also
demonstrated that 4-MMC is a transporter substrate at NET, DAT, and SERT, similar to the
pharmacological effects of 3,4-methylenedioxymethamphetamine (MDMA or Ecstasy) (Baumann et al.,
2012); although, 4-MMC has a comparatively stronger binding affinity to DAT. Indeed, Kehr et al. (2011)
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found that injections (sc) of 3.0 mg/kg 4-MMC in rats produced time-dependent increases in extracellular
dopamine levels in the nucleus accumbens (peak at 496% of control), as determined using microdialysis
procedures. In that study, 3.0 mg/kg 4-MMC also produced statistically greater levels of dopamine and
serotonin in the rats when compared to saline-treated controls. In addition to these findings, Simmler et al.
(2013) demonstrated that 4-MMC also possesses relatively strong binding affinity (i.e., K i: 2.1 ± 0.7) for
serotonin 5-HT2A receptors. Further, Eshleman et al. (2013) observed that 4-MMC functions as an
antagonist of inositol-1-phosphate formation at serotonin h5-HT2A receptors, indicating that this drug elicits
intracellular events that may further modulate neural activity. For a current review of MDPV and 4-MMC’s
pharmacological properties, see Valente, Guedes de Pinho, de Lourdes Bastos, Carvalho, and Carvalho
(2014).
In addition to studies that have examined the acute pharmacological effects of MDPV and 4-MMC
at receptor targets in the central nervous system, other reports have demonstrated that these drugs produce
effects on peripherally-located targets (i.e., outside the CNS) as well. For example, Araújo et al. (2015)
demonstrated that MDPV produces cytotoxicity in rat hepatocytes, similar to the effects of MDMA.
Shortall, Green, Swift, Fone, and King (2012a), found that 10 mg/kg 4-MMC produced a decrease in tail
and rectal temperature in adult male Lister hooded rats. Similar hypothermic effects of 4-MMC have been
demonstrated elsewhere (e.g., Shortall et al., 2012b; Wright et al., 2012; Miller et al., 2013). Contrary to 4MMC, MDPV produces dose- and ambient-temperature-dependent hyperthermic effects measured using
peripherally-located telemetry devices in mice (e.g., Fantegrossi, Gannon, Zimmerman, & Rice, 2013).
Kiyatkin, Kim, Wakabayashi, Baumann, and Shaman (2015) observed similar effects, with MDPV
producing dose-dependent increases in brain temperature. Given that all drugs produce multiple effects at
the behavioral level or physiological level of analysis, such findings highlight the need of evaluating drug
effects in targets beyond the central nervous system.
Polysubstance use in humans. Although not directly relevant to the experiment described herein,
it is noteworthy that polysubstance use is commonplace in the consumption of illicit or legal drugs. In some
cases, simultaneous use of multiple drugs may pose greater health and safety risks to users given the
combined actions of the drugs. A recent study observed that among a sample of 30 deceased individuals
aged 16-24 years old in the United Kingdom who used 4-MMC, 63% died due to accidental poisoning and
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87% used 4-MMC with other drugs (Loi et al., 2015). It may be that users combine other drugs with the
synthetic cathinones to enhance their stimulant and euphoric effects. Previous reports on human
consumption of MDPV and 4-MMC indicated that these substances produce interoceptive stimulus effects
similar to other illicit drugs, such as cocaine and MDMA (Winstock et al., 2011a;b; for review, Ross,
Reisfield, Watson, Chronister, & Goldberger, 2012), however, further research is necessary to understand if
drug combinations lead to a desired increase in subjective effects.
Regardless of whether users achieve the desired combined effects of mixing bath salts with other
drugs, or if even they consume mixtures knowingly, recent toxicology reports have documented cases in
which human users simultaneously displayed levels of synthetic cathinones and other drugs present in
bodily fluids (e.g., Wyman et al., 2013; Murray, Murphy, & Beuhler, 2012; Aromatario, Bottoni, Santoni,
& Ciallella, 2012; Lusthof et al., 2011). These findings indicate that polysubstance use may be common
among synthetic cathinone users, although, as mentioned, further research is necessary to confirm if the
drugs are knowingly consumed together, or if users acquire the drugs already mixed. In any event,
non-human research indicates that simultaneous exposure to bath salt constituents with other drugs may
pose greater health risks to users, including enhanced neurotoxicity. For example, recent studies have
demonstrated in mice that pretreatment with 4-MMC enhanced dopamine nerve ending toxicity produced
by methamphetamine, amphetamine, or MDMA (Angoa-Pérez et al., 2013); however, in a later study
(Angoa-Pérez, Kane, Herrera-Mundo, Francescutti, & Kuhn, 2014), 4-MMC pretreatment appeared to
produce no effect on the health of serotonin nerve endings. Contrariwise, Anneken, Angoa-Pérez, and
Kuhn (2015) observed that MDPV pretreatment in mice attenuated methamphetamine-induced dopamine
nerve ending neurotoxicity. The authors of that study suggested that substrates for DAT (e.g. 4-MMC)
appear to enhance methamphetamine neurotoxicity, but blockers at DAT (e.g., MDPV) may have a
neuroprotective effect. Further research is necessary to dissociate the relative effects of monoamine
transporter blockers from substrates in terms of pharmacologically-induced neurotoxicity. In any case, it
remains to be determined if early exposure to MDPV or 4-MMC produces similar effects in recreational
human drug users. Future studies examining the effects of ecologically-relevant drug mixtures on
biological and behavioral measures seems warranted.
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Locomotor effects and ambulatory sensitization. It is common in behavioral pharmacology
research to evaluate drug effects on ambulatory measures in non-human models. Some researchers have
suggested that all drugs producing locomotor-stimulant effects possess addiction potential, largely because
such drugs stimulate dopaminergic pathways that are associated with “approach behaviors” (see Wise &
Bozarth, 1987). Nevertheless, current views submit that changes in dopaminergic activity (e.g., increases in
dopamine efflux) are not common to all misused drugs (for review, Nutt, Lingford-Hughes, Erritzoe, &
Stokes, 2015), and therefore, current research efforts should consider a broader spectrum of
drug-receptor-pathway mechanisms responsible for drug misuse and chemical dependencies. Consistent
with traditional precedence, recent studies have examined the locomotor effects of MDPV and 4-MMC.
Several of these experiments are reported below.
Shortall et al. (2013) injected rats (ip) with 1 or 4 mg/kg (-)-cathinone 1, 4, or 10 mg/kg
(±)-4-MMC-HCl, 10 mg/kg (±)-MDMA-HCl, or saline and measured locomotor activity for 60 min. The
results revealed that rats injected with 10 mg/kg 4-MMC, 10 mg/kg MDMA, and 1 or 4 mg/kg cathinone
displayed statistically greater levels of activity than saline-treated rats. Lisek et al. (2012) demonstrated that
pretreatment with a dopamine D1 receptor antagonist (SCH 23390; 0.5 mg/kg) attenuated the acute
locomotor stimulant effects of 5 mg/kg 4-MMC, and pretreatment with a dopamine D2 receptor antagonist
(sulpiride; 40 mg/kg) enhanced the acute effects of 5 mg/kg 4-MMC in male Sprague-Dawley rats. MDPV
is comparatively more potent than 4-MMC at producing locomotor-stimulant effects in rodents. For
example, Gatch, Taylor, and Forster (2013) demonstrated that mice injected with MDPV (1, 3, or 10
mg/kg) displayed statistically greater, time-dependent levels of ambulation counts compared to
saline-treated mice, whereas in the same study, only 3 or 10 mg/kg 4-MMC produced greater levels of
ambulation counts than saline-treated mice; although, it is worth noting that the ED50 values for locomotor
activity did not differ between the MDPV-treated- (1.26 ± 0.08; expressed in mg/kg as mean ± SE) and
4-MMC-treated mice (1.38 ± 1.22). Aarde, Huang, Creehan, Dickerson, and Taffe (2013a) demonstrated
that male Wistar rats injected (sc) with 0.5 or 1.0 mg/kg MDPV displayed statistically greater,
time-dependent increases in locomotor activity counts compared to saline-treated rats. For an excellent
review of the locomotor effects of 4-MMC and MDPV in rodents, see Gregg and Rawls (2014).
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In addition to evaluations of the acute locomotor effects of MDPV and 4-MMC, other research has
assessed the effects of repeated exposure to these drugs on ambulatory responses. If a subject’s ambulatory
responses progressively increase as function of repeated and intermittent drug exposure, this phenomenon
is termed “behavioral sensitization”. Evidence of drug-induced behavioral sensitization is suggested to
reflect neuroadaptive changes in brain areas that are implicated in compulsive drug use and forming
chemical dependencies (Pierce & Kalivas, 1997; Robinson & Berridge, 2001), and involve physiological
pathways that are affected by prototypical psychostimulants (Vanderschuren & Kalivas, 2000). It is worth
nothing that the behavioral data recorded using sensitization procedures seems most applicable for
evaluating if repeated drug exposure produces progressive increases in drug sensitivity (cf. tolerance). Such
drug sensitivity is subject to a variety of procedural variables (e.g., drug exposure and activity recording
occurs in the same context instead of a different context; see Ohmori, Abekawa, Ito, & Koyama, 2000;
Phillips, Pastor, Scibelli, Reed, & Tarragón, 2011). Accordingly, behavioral sensitization procedures are
commonly used in preclinical research to characterize the behavioral effects of psychoactive substances
under specific experimental conditions.
Recent studies have demonstrated 4-MMC-induced ambulatory sensitization in mice (Lisek et al.,
2012; Berquist, Peet, & Baker, 2015) and rats (Gregg, Tallarida, Reitz, McCurdy, & Rawls, 2013). In
addition, Gregg, Tallarida, Reitz, and Rawls (2013) demonstrated that 4-MMC cross-sensitizes to the
stimulant effects of cocaine in Sprague-Dawley rats. At the time of this writing, Berquist and Baker
(unpublished findings) and Berquist, Traxler, Mahler, and Baker (2016) completed several studies that
tested doses of MDPV or 4-MMC using locomotor sensitization procedures. The studies conducted at
Western Michigan University were not completed to evaluate the effects of MDPV or 4-MMC on levels of
locomotor activity per se, but rather to assess if these drugs enhanced (or suppressed) the locomotor effects
of other drugs (e.g., cocaine) when combined in mixtures. Based on these studies, adult male
Sprague-Dawley rats injected with 0.5 mg/kg MDPV displayed within-group sensitization (i.e., day 7
horizontal activity was statistically greater than day 1 activity following a seven-day consecutive,
daily-dosing procedure), rats previously injected with select mixtures of MDPV and 4-MMC displayed
statistically greater, time-dependent levels of horizontal activity following an acute injection of cocaine (5
mg/kg) compared to rats previously injected with saline (Berquist, Traxler, Mahler, & Baker, 2016), and
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there is some evidence collected in-house suggesting that in mice, there may be differences in sensitivity to
the locomotor stimulant effects of mixtures of MDPV and 4-MMC depending on subject sex. Based on
these findings, and other studies completed at Western Michigan University (manuscripts in preparation), it
is predicted that the locomotor sensitization assay will serve as a useful model of exploring the behavioral
effects of drug mixtures.
Models of reinforcement and reward. Procedures for evaluating the reinforcing or rewarding
effects of drugs include response-dependent (e.g., intravenous self-administration) and
response-independent components. Nonhuman experimental subjects are most often used in behavioral
pharmacology research given practical and ethical restraints. It is important to recognize that with each of
the models, laboratory control over extraneous (but perhaps socially or clinically relevant) variables is
extensive. As such, data analysis and interpretations resulting from these procedures should be especially
meticulous. Discussed next are three models that are commonplace in preclinical drug use research:
intravenous-self administration, intracranial self-stimulation, and conditioned place preference. Tables 1
and 2 display previous studies that have assessed the behavioral effects of MDPV and 4-MMC,
respectively, using these procedures. Further, below are discussions of select studies for additional
exposition and detailed description to familiarize readers with the general experimental questions addressed
using these procedures and the associated data path analyses.
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Table 1
Reinforcing and Rewarding Effects of MDPV
Procedure

Dose
0.05, 0.1, 0.2
mg/kg/infusion

Subjects
♂SpragueDawley rats

Results
Reference
All doses of MDPV
Watterson et al.
IVSA
maintained IVSA
(2012)
MDPV potency and
0.05 mg/kg/inf
♂Wistar rats efficacy >
Aarde et al. (2013a)
methamphetamine
MDPV = α-PVP as
0.05 mg/kg/inf
♂Wistar rats
Aarde et al. (2015a)
SR+
MDPV binge rats
displayed post0.05 mg/kg/inf
♂Wistar rats
Aarde et al. (2015b)
acquisition decrease in
wheel-running
MDPV maintained
♂Sprague0.03 mg/kg/inf
IVSA; similar to 0.5
Schindler et al. (2016)
Dawley rats
mg/kg/inf cocaine
0.1, 0.5, 1, 2
♂SpragueMDPV lowered ICSS
Watterson et al.
ICSS
mg/kg
Dawley rats thresholds at all doses
(2012)
MDPV was second (to
♂Spraguemethcathinone) most
0.32-3.2 mg/kg
Bonano et al. (2014a)
Dawley rats potent to facilitate
ICSS
♂SpragueMDPV facilitated
3.2 mg/kg
Bonano et al. (2014b)
Dawley rats ICSS
S(+)MDPV potency >
0.32-10 mg/kg
♂Sprague(±)MDPV at
(+)MDPV or
Kolanos et al. (2015)
Dawley rats facilitating ICSS
(-)MDPV
(dose-dependent)
All doses produced
evidence of CPP. 5
0.5, 2, 5, 10, 20
♂C57BL/6
and 10 mg/kg MDPV
Karlsson et al. (2014)
CPP
mg/kg
mice
> amphetamine CPP at
same doses
1.8 and 3.2 mg/kg
♀ and ♂
1, 1.8, or 3.2
MDPV produced CPP
SpragueKing et al. (2015a)
mg/kg
across male and
Dawley rats
female rats
All doses produced
1, 1.8, or 3.2
♂Spragueincreases in time-spent
King et al. (2015b)
mg/kg
Dawley rats in drug-paired
chamber
IVSA = intravenous self-administration; ICSS = intracranial self-stimulation; CPP = conditioned place
preference
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Table 2
Reinforcing and Rewarding Effects of 4-MMC
Procedure
IVSA

Dose
0.24
mg/kg/infusion
0.3 mg/kg/inf
0.5 or 1.0
mg/kg/inf

ICSS

0.5 mg/kg/inf

♀Wistar rats

0.5 mg/kg/inf

♂Wistar rats

0.5 mg/kg/inf

♂Wistar rats

1, 3, or 10 mg/kg

♂C57BL/6J
mice

1-10 mg/kg

♂SpragueDawley rats

R-and S-isomers
(1-10 mg/kg)
CPP

Subjects
♂SpragueDawley rats
♂SpragueDawley rats
♂SpragueDawley and
Wistar rats

30 mg/kg
0.5, 2, 5, 10, or 20
mg/kg
10 or 25 mg/kg
10, 100, or 500
μM
R-isomer and Sisomer (5-30
mg/kg)
R-isomer, Sisomer, and
racemate (10, 100,
250 μM)

♂SpragueDawley rats
♂SpragueDawley rats and
♂CD-1 mice
♂C57BL/6 mice
♂Swiss CD-1
mice
Planarians
(Dugesia
dorotocephala)
♂SpragueDawley rats
Planarians
(Dugesia
dorotocephala)

Results

Reference

MC maintained IVSA

Hadlock et al. (2011)

MC IVSA >
methamphetamine IVSA

Motbey et al. (2013)

MC maintained IVSA

Aarde et al. (2013b)

MC infusion rates >
methylone during MDMA
acquisition
MC intake > MDMA or
methylone during 2h
access
Long-access-trained rats
displayed > breakpoints
during MC and
methamphetamine tests
MC potentiates brain
stimulation reward
ICSS same as MDPV
above; MC < potent at
facilitating ICSS
R produced greater ICSS
facilitation than S
30 mg/kg elicited CPP in
rats and mice
5 and 20 mg/kg elicited
CPP
10 and 25 mg/kg elicited
CPP

Creehan et al. (2015)
Vandewater et al.
(2015)

Nguyen et al. (2016)

Robinson et al. (2012)
Bonano et al. (2014a)
Gregg et al. (2015)
Lisek et al. (2012)
Karlsson et al. (2014)
Ciudad-Roberts et al.
(2015)

100 and 500 μM elicited
CPP

Ramoz et al. (2012)

30 mg/kg R produced
CPP; S did not produce
CPP

Gregg et al. (2015)

10, 100, 250 μM R and
100 μM racemate elicited
CPP

Vouga et al. (2015)

Brown
planarians
1 or 10 μM failed to elicit
Hutchinson et al.
1 or 10 μM
(Dugesia
CPP
(2015)
Tigrina)
MC = 4-MMC; IVSA = intravenous self-administration; ICSS = intracranial self-stimulation; CPP =
conditioned place preference
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Self-administration. Drug self-administration procedures are useful in behavioral pharmacology
research for investigating the relative reinforcing value of drugs (for review, Young & Herling, 1986).
Notably, self-administration methods make available direct comparisons of the reinforcing efficacy
between different drugs, or to non-drug reinforcers/activities. In addition, experimental subjects can be
exposed to a variety of potential pharmacotherapeutics and environmental manipulations (i.e., non-drug
manipulations) to determine if such interventions reduce response-dependent drug infusions.
Recently, extensive use of self-administration procedures has broadened understanding of the
relative reinforcing value of MDPV compared to other drugs and non-drug reinforcers. For example,
Watterson et al. (2012) reported the first experiment to assess the reinforcing efficacy of MDPV (0.05, 0.1,
or 0.2 mg/kg/infusion) using intravenous self-administration in rats. The results revealed that all doses of
MDPV supported self-administration, and that MDPV produced patterns of responding under a
progressive-ratio schedule similar to methamphetamine (0.05 mg/kg/infusion). These results indicate that
MDPV serves a potent reinforcer that may possess potential for drug misuse. In a similar study, Aarde,
Huang, Creehan, Dickerson, and Taffe (2013) compared the relative reinforcing efficacy of 0.05
mg/kg/infusion MDPV to 0.05 mg/kg/infusion d-methamphetamine using intravenous self-administration
procedures in male Wistar rats. The results of this study revealed that MDPV supports intravenous
self-administration in male Wistar rats, and that the infusion rates and number of responses that occurred
under a progressive-ratio schedule were greater with MDPV than methamphetamine.
Previous research has also investigated the reinforcing efficacy of MDPV in comparison to
non-drug reinforcers. Aarde, Huang, Dickerson, and Taffe (2015) assessed in Wistar rats whether
opportunities to receive 0.5 mg/kg/infusion MDPV would lessen the relative reinforcing value of access to
a running wheel. The results of this study revealed that as a binge-like pattern of MDPV self-administration
occurred in an individual rat, there existed a corresponding decrease in the amount of time allocated to a
concurrently-available running wheel. These findings suggest that observing individual differences in
acquiring MDPV self-administration is the rule rather than the exception (a fact of most self-administration
experiments and of drug consumption in general), and that MDPV as a reinforcer may compete with
ecologically-relevant reinforcers present in a user’s environment. Further comparisons of MDPV’s
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reinforcing efficacy to other non-drug, but ecologically-relevant activities, seems worthwhile in light of the
foregoing data.
Previous research has also investigated the relative reinforcing value of 4-MMC using
self-administration procedures. In the first known report, Hadlock et al. (2011) observed that male
Sprague-Dawley rats would reliably lever-press to receive 4-MMC (0.24 mg per 10μl infusion) under an
FR1 schedule of drug reinforcement. In addition, rats displayed an increase in the total number of responses
that produced 4-MMC delivery as the number of sessions increased. These findings demonstrate that
4-MMC supports self-administration using rodent behavioral procedures. Subsequent studies have reported
similar findings as those found in Hadlock et al. (2011). For example, Motbey et al. (2013) observed that
male Sprague-Dawley rats would reliably nose-poke to receive 0.03 mg/kg/infusion 4-MMC. Under a
progressive-ratio schedule, the rats displayed increases in the number of active nose-pokes (i.e., nose-pokes
that produced drug delivery) and infusions as the dose of 4-MMC increased. In addition, rats displayed
similar values of active pokes and infusions under 4-MMC to methamphetamine, suggesting that 4-MMC
may possess reinforcer efficacy similar to methamphetamine (Motbey et al., 2013).
In a recent study, Vandewater, Creehan, and Taffe (2015) compared levels of intravenous
self-administration between 4-MMC, MDMA, or 3,4-methylenedioxymethcathinone (methylone) in male
Wistar rats responding under an FR1 schedule of drug reinforcement. Compared to methylone- or
MDMA-trained rats, 4-MMC-trained rats displayed the highest infusion levels during the acquisition phase,
and the “high-preference” subgroup in the 4-MMC-trained rats (i.e., the upper portion of the median split in
infusion levels among rats) also showed increases in breakpoints when responding to receive infusions of
4-MMC, MDMA, and methylone. Overall, these findings support the results of previous reports indicating
that 4-MMC may possess relatively high abuse potential among users, especially in comparison with other
drugs of abuse, such as MDMA and methylone (Vandewater, Creehan, & Taffe, 2015).
It is noteworthy that the aforementioned self-administration studies were conducted using male
rats as experimental subjects. Comparisons of the effects of drug treatments on behavioral measures using
female rats is less common in behavioral pharmacology research. Nevertheless, recent experiments have
used female subjects to assess effects of synthetic cathinones on behavioral and physiological measures. Of
particular interest, Creehan, Vandewater, and Taffe (2015) reported that female Wistar rats reliably
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intravenously self-administered 0.5 mg/kg/infusion 4-MMC and the infusion rates were higher than 0.5
mg/kg/inf MDMA- or 0.5 mg/kg/inf methylone-trained rats. In sum, these findings support the foregoing
self-administration reports that used 4-MMC as a training drug in rats, and that 4-MMC serves as a
relatively potent reinforcer in a variety of self-administration preparations. Other reports that have
investigated the behavioral and physiological effects of the synthetic cathinones using female subjects are
discussed below.
Intracranial self-stimulation. Although the self-administration assay provides the most direct
measure of evaluating the reinforcing efficacy of a drug, intracranial self-stimulation (ICSS) procedures are
also common in preclinical research. Unlike the self-administration paradigm where drug delivery is
response-dependent, ICSS procedures include the use of an artificial stimulus (e.g., electric current) and
inferential reasoning to evaluate the rewarding value of a drug. For example, the median forebrain bundle is
commonly used as the target brain region to receive electrical stimulation. This bundle is typically selected
because of its well-characterized innervations with brain regions involved in drug addiction and reward,
such as the nucleus accumbens. In general rodent preparations, it is typical that injections of drugs with
abuse potential delivered prior to opportunities for responding to receive electrical stimulation will reduce
the overall stimulation; that is, pretreatment with drugs of abuse tend to decrease subsequent
response-dependent electrical stimulation. If an ICSS experiment reveals that some novel drug or drug
heretofore untested reduces overall stimulation, then the drug is considered to possess abuse potential.
Although the ICSS assay seems predictive of a drug’s abuse potential, the findings should be interpreted
with caution given that the subjects are not responding to receive the drug itself (cf. self-administration
procedures).
In a recent study, Kolanos et al. (2015) evaluated the stereochemistry of MDPV optical isomers
using ICSS procedures. The authors reported that S(+)-MDPV dose-dependently facilitated ICSS and was
more potent that racemic MDPV under similar testing conditions. In contrast, R(-)-MDPV failed to affect
ICSS rates at all doses tested. In addition to MDPV, previous reports have assessed the stereochemistry of
4-MMC using ICSS procedures. Gregg et al. (2015) revealed that (R)-4-MMC produced greater ICSS
facilitation than the (S)-4-MMC isomer. In addition, (R)-4-MMC more potently released [3H]MPP+ (the
radiolabeled substrate) at DAT in rat synaptosomes, compared to (S)-4-MMC. The authors of that study
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concluded that their findings warrant further studies evaluating the neurochemistry and behavioral effects
of 4-MMC optical isomers. Although noted in their discussion that some illicitly-synthesized compounds
(e.g., methcathinone) contain larger portions of one enantiomer over another in mixture, there are no known
published studies on the prevalence of one enantiomer of 4-MMC over another in drug mixtures, or if
enantiomers are region-specific (i.e., variant drug market availability). Similar ambiguity exists for MDPV;
only additional research can determine if continued investigations of synthetic cathinone stereochemistry is
a pragmatic issue with these substances.
Conditioned place preference. Conditioned place preference (CPP) procedures are useful for
predicting the rewarding effects of drugs produced by Pavlovian conditioning processes (although,
evidence of place preference may not be unequivocally attributable to Pavlovian conditioning processes;
see, Huston, de Souza Silva, Topic, & Müller, 2013). CPP procedures involve repeated intermittent pairing
of drug-associated cues with a distinct environment, and subsequent assessment of a subject’s time spent in
that environment. As such, CPP procedures are useful for assessing whether the rewarding effects of drugs
can be paired with contextual cues, and, if so, such cues may further prompt drug craving and relapse
among human users. Lisek et al. (2012) observed that male Sprague-Dawley rats and male CD-1 mice
injected with 30 mg/kg 4-MMC during the place conditioning trials displayed statistically greater levels of
preference scores than saline-treated rats or mice, respectively. In a later study, Karlsson, Andersson,
Kronstrand, and Kugelberg (2014) investigated whether 4-MMC, MDPV, and methylone would produce
CPP in male C57BL/6 mice. Results from this study revealed that mice injected with 0.5 or 20 mg/kg
4-MMC, or any dose of MDPV (0.5, 2, 5, 10, or 20 mg/kg) during the place conditioning trials displayed
statistically greater levels of drug-paired preference scores compared to saline-treated mice. In addition,
mice injected with 5 or 10 mg/kg MDPV displayed greater levels of preference scores compared to mice
injected with similar doses of amphetamine.
Similar to the findings reported by Karlsson, Andersson, Kronstrand, and Kugelberg (2014), King,
Wetzell, Rice, and Riley (2015) observed in male Sprague-Dawley rats that 1.0, 1.8, and 3.2 mg/kg MDPV
produced statistical differences in the percent of time in the drug-paired side across conditioning sessions
(i.e., preconditioning and post-conditioning); however, the authors noted that the rats did not actually spend
more time in the drug-paired side than the unpaired side during the post-conditioning session. Moreover,
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the effects were not dose-dependent. As such, this experiment also demonstrates that results should be
interpreted with caution because evidence of statistical effects may be due to data handling rather than clear
drug effects.
Thus far, the foregoing studies on the synthetic cathinones have included rodents as experimental
subjects. Nevertheless, recent interests have shifted to consider organisms with relatively ‘simpler’ nervous
systems (i.e., fewer neurons, well-characterized genomes). Recently, Hutchinson, Prados, and Davidson
(2015) assessed in brown planaria (Dugesia Tigrina) whether 1 or 10 μM of cocaine or 4-MMC would
elicit CPP. The results revealed that both doses of cocaine produced evidence of place preference, however
neither dose of 4-MMC elicited place preference in the subjects. Contrary to the results of Hutchinson,
Prados, and Davidson (2015), Ramoz et al. (2012) observed that 100 and 500 μM of 4-MMC produced
evidence of place preference in planaria (Dugesia dorotocephala). Discrepancies between the results of this
study and Hutchinson, Prados, and Davidson (2015) are likely due to the different doses of 4-MMC tested,
the different planaria strain used, and the procedures used for drug conditioning (e.g., Ramoz et al., 2012)
evaluated CPP among the subjects in a single day and Hutchinson et al. used multiple days of drug
conditioning). Nonetheless, these findings together suggest that the effects of 4-MMC on place preference
in planaria are dose-dependent and, importantly, that similar responses to 4-MMC may occur across
species. It is admirable that these studies demonstrated comparable CPP effects in invertebrates, such as
planaria, to experimental subjects that are generally “by default” selected as experimental subjects (viz.
rodents). Toward the bioethical goal of reduction, refinement, and replacement among non-human subjects
used in scientific research, a shift from using vertebrates to invertebrates in drug use research is a
commendable endeavor.
Drug Discrimination
Background. Findings from state-dependent learning experiments demonstrated that experimental
subjects could display one response in the presence of a drug, and another response in its absence.
Specifically, early findings including state-dependent learning procedures revealed that a drug’s
interoceptive stimulus effects affected the acquisition and performance of learned responses—subjects
would display better performance if the stimulus conditions (e.g., drug exposure) during the acquisition
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phase were identical to the stimulus conditions in the performance phase 3. From these previous statedependent learning studies, emerged drug discrimination (DD) methods that would eventually develop into
a validated assay for measuring a drug’s discriminative stimulus effects (see Colpaert, 2011).
Over decades, the DD paradigm has undergone considerable procedural transformations (see
Glennon & Young, 2011b). Early DD preparations consisted of a T-maze apparatus (e.g., Overton, 1982)
which required subjects (typically rodents) to discriminate between the “left” or “right” arm of the maze
conditional upon the presence or absence of a drug’s interoceptive effects during the testing session.
Single-lever operant procedures using operant conditioning chambers soon replaced the T-maze preparation
to improve and standardize DD procedures in general, and to provide additional measurement of a drug’s
behavioral effects (e.g., a drug’s effects on rate of responding). Operant conditioning chambers of variable
dimensions and components were also developed to test behavioral effects of drugs in several species, such
as rats, mice, rabbits, pigeons, and primates. Accordingly, the foregoing T-maze procedures seemed to have
been abandoned by most drug discrimination researchers, although, rarely, such procedures are used in
current times.
Experimental research using DD procedures increased considerably in the mid-20th century.
Researchers across a range of disciplines (e.g., behavioral pharmacologists, medicinal chemists) further
expanded the DD assay to accommodate several training drugs (e.g., equipping an operant conditioning
chamber with multiple levers), test whether a drug’s behavioral effects are conditional on variable
environmental factors (e.g, schedules of reinforcement), and test other behavioral processes (e.g.,
respondent relations and conditioned taste aversion procedures). As mentioned, a common DD preparation
comprises two-lever rodent operant conditioning chambers using food, water, or sweetened milk as
reinforcers for lever-press responding. The most common schedules of reinforcement used in DD
experiments are fixed-ratio schedules, although experimenters have tested using a variety of other
schedules and schedule combinations (second-order schedules) (see Glennon & Young, 2011b).
The most common uses of DD methods are to characterize drugs’ interoceptive effects or reveal
receptor isoforms that are involved in mediating their discriminative stimulus properties. Drug
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In the behavioral literature, a decrease in performance as a function of dissimilar stimulus conditions
during acquisition and performance can be referred to as “stimulus-change decrement”.
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classification is valuable for determining the interoceptive effects of a novel or emerging drug. For
example, if a novel β-ketoamphetamine appears in the public domain, it is valuable to know if the drug
produces subjective effects in users similar to other illicit drugs, such as methamphetamine, cocaine, or
MDMA. Most DD experiments include stimulus substitution tests (or stimulus generalization tests) to
determine if the interoceptive cue produced by some other drug of interest resembles the cue produced by
the training drug. Specifically, in the case of a rodent operant chamber using mechanical levers, stimulus
substitution tests assess the extent to which a test drug exerts stimulus control over lever-press responding
in comparison to a training drug’s control over lever-press responding. Moreover, DD procedures are
valuable for assessing whether a specific dose of a novel training drug tested using specified procedures
produces effects similar to other well-characterized drugs of abuse. Such information could be useful for
informing the public, private, and government sectors about the drug’s effects. In addition, drugs with
effects known to be centrally-mediated (i.e., effects produced by stimulation in the central nervous system)
can be distinguished from drugs with peripherally-mediated effects using DD procedures.
As mentioned, a second use of DD procedures is to reveal receptor isoforms that are involved in
mediating a drug’s discriminative stimulus effects. For example, if test doses of cocaine produce full
substitution to a training dose of the aforementioned β-ketoamphetamine, then it is possible that the
stimulus effects produced by the β-ketoamphetamine may be mediated by dopamine receptor activation
(note: drugs with variable physiological effects can produce comparable interoceptive effects). Moreover,
this possibility can be further assessed by pretreating the subjects trained on the dose of the
β-ketoamphetamine with drugs that possess selective binding affinities to dopamine receptor isoforms. For
example, experimental subjects can be injected with doses of a selective D2 receptor antagonist (e.g.,
haloperidol) prior to receiving doses of the training drug. As long as the experimenter properly accounts for
the pharmacokinetics of haloperidol and the β-ketoamphetamine, then the subject’s responses may reflect
whether D2 receptor activation is involved in mediating the training drug’s stimulus cue (e.g., if there is a
downward [reduction in efficacy or maximal effect] or leftward shift [reduction in potency] in the training
drug’s dose-response curve). Overall, stimulus blockade studies may assist in future research efforts
devoted toward developing pharmacotherapies for drug users and inform researchers of potential protein
receptors involved in mediating a drug’s effects.
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On a final note, it is noteworthy that rodents and pigeons will respond to a drug’s interoceptive
effects during DD procedures in a manner similar to other species, including humans (e.g., in experimental
settings where humans are pushing buttons to receive points or money under some specified schedule of
reinforcement). Therefore, DD methods are useful for investigating a drug’s effects when such methods are
precluded for use in humans, which is true in most general cases. It is also worth emphasizing that a variety
of environmental variables are known to modulate a drug’s effects (e.g., Poling, 2000), suggesting that a
drug’s interoceptive “cue” is differentially expressed depending upon the environmental context in which
drug exposure takes place. Nevertheless, relatively few experimental procedures, beyond DD, exist that
permit investigations of a drug’s possible interoceptive effects. For more comprehensive historical and
procedural descriptions of the DD paradigms, readers are referred elsewhere (Solinas, Panlilio, Justinova,
Yasar, & Goldberg, 2006; Young, 2009; Glennon & Young, 2011b).
Quantal versus graded dose-response effects. Drug discrimination data are generally analyzed
(and conceptualized) using one of two approaches. The first, referred to as the “quantal” approach, states
that subjects’ responses occur in an all-or-none fashion (a nominal dependent variable). That is, the
discriminative cue is either present or it is not (compare a drug’s interoceptive effects to an on and off
switch). In contrast, the second, referred to as the “graded” approach, states that subjects’ responses are
proportional to a dose of a drug (an ordinal or interval dependent variable). That is, subjects will display
greater levels of stimulus generalization as the dose of a drug increases (assuming the test drug produces an
interoceptive cue that resembles the cue produced by the training drug). The graded approach seems most
common in the recent drug discrimination literature, possibly due to the development of simplified
statistical procedures that can easily analyze graded dose-response functions (for a brief review on this
subject, see Glennon & Young, 2011c). Nevertheless, theoretical debates between individuals who promote
these approaches has prompted interesting discussions and conceptualizations about drug discrimination
data (see the Discussion below for more information regarding quantal versus graded drug discrimination
data).
MDPV and 4-MMC in drug discrimination. Relatively few studies have investigated the
discriminative stimulus effects of MDPV and 4-MMC using DD methodology. In the first known study to
use a dose of MDPV as a training drug, Fantegrossi, Gannon, Zimmerman, and Rice (2013) observed in 0.3
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mg/kg MDPV-trained mice responding under a FR 20 – 10-s time-out procedure of sweetened milk
reinforcement that racemic MDPV, racemic MDMA, and methamphetamine produced full substitution.
Contrariwise, a cannabinoid receptor CB1 and CB2 agonist, JWH-018, and an opioid receptor agonist,
morphine, failed to produce full substitution. These authors used a cumulative dosing procedure to generate
a complete dose-response curve for each test drug in a single testing session. Each test drug
dose-dependently reduced response rate as well. Overall, these authors concluded that the interoceptive
effects of MDPV may be similar to the cues produced by methamphetamine and MDMA.
Similar to the study above, Varner et al. (2013) revealed that in 3.2 mg/kg 4-MMC-trained
Long-Evans rats, MDMA produced full substitution, and cocaine and methamphetamine produced high
partial substitution (75.86% and 72.86% drug-appropriate responding, respectively). Contrariwise,
morphine, fenfluramine (serotonin releaser), and phencyclidine (glutamate NDMA receptor antagonist)
failed to produce complete generalization in the 4-MMC-trained rats. In addition, Varner et al. pretreated
rats with a selective dopamine D2 receptor antagonist (haloperidol) to evaluate if the D2 receptor was
involved in mediating 3.2 mg/kg 4-MMC’s discriminative cue. The results of the blockade tests revealed
that 0.032 and 0.1 mg/kg haloperidol failed to block the 3.2 mg/kg 4-MMC cue. Thus, Varner et al.
suggested that dopamine D2 receptor activation may not be involved in mediating 4-MMC’s subjective
effects.
Other studies have evaluated whether MDPV or 4-MMC would substitute in rodents trained under
other drugs or drug mixtures. Gatch, Taylor, and Forster (2013) found that in 10 mg/kg cocaine- or 1 mg/kg
methamphetamine-trained mice that MDPV and 4-MMC produced full substitution. Given these findings,
Gatch et al. concluded that MDPV and 4-MMC produce behavioral effects (i.e., interoceptive effects) that
are comparable to cocaine and methamphetamine. In a later study, Harvey and Baker (2016) demonstrated
that MDPV produced full substitution in male Sprague-Dawley rats trained to discriminate a mixture of
MDMA (1.5 mg/kg) and d-amphetamine (0.5 mg/kg) from saline, but not in another group of rats trained to
discriminate 1.5 mg/kg MDMA from saline. In addition, 4-MMC produced full substitution in both of the
foregoing training groups. Overall, the authors of that study suggested that, unlike MDPV, the interoceptive
effects of 4-MMC might involve serotonin release. Further research using compounds with selective
affinities for serotonin receptors may support this hypothesis.
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Current Research Objective
To further characterize the discriminative stimulus effects of MDPV and 4-MMC, groups of male
Sprague-Dawley rats were trained to discriminate 0.3 mg/kg MDPV or 1.0 mg/kg 4-MMC from saline, in a
two-lever drug discrimination task. The main objective of this experiment was to generate dose-response
curves of the following test drugs in these training groups: MDPV, 4-MMC, d-amphetamine,
(+)-methamphetamine, (-)-cocaine, MDMA, (+)-LSD, and (+)-fenfluramine.

METHODS

Subjects
Sixteen male Sprague-Dawley rats weighing 350-400g (Charles River Laboratories Inc., Kingston,
NY, USA) were singly housed in polycarbonate cages with corncob bedding (ENVIGO, Madison, WI,
USA) in a temperature and humidity controlled vivarium maintained on a 12/12h light/dark cycle (lights on
at 0800h). Rats were maintained at 85-90% of free-feeding weights through restricted daily food rations
(LabDiet®, PMI® Nutrition LLC., Brentwood, MO, USA), but access to water was unrestricted in the
home cages. All procedures were conducted in accordance with the Guide for the Care and Use of
Laboratory Animals (2013) and were approved by the Institutional Animal Care and Use Committee at
Western Michigan University.
Apparatus
Eight computer-operated standard three-lever rat operant chambers (ENV-100; MED Associates,
St. Albans, VT, USA) contained in sound-attenuating cabinets equipped with fans for ventilation and
masking noise were used for all training and testing sessions. The operant chambers consisted of an acrylic
top, side, and door panel, with other walls and components made of stainless steel. A houselight (28V)
located near the top of the rear stainless panel of the chamber provided illumination during all sessions.
Three retractable levers were located above a stainless steel barred floor. Two levers were equidistant from
a center food magazine on the front wall, while a third lever was located directly beneath the food
magazine. Food reinforcers consisted of 45mg powderless food pellets (Bioserv, Frenchtown, NJ, USA).
All experimental events were recorded using Med-PC software Version IV (Med-Associates, St. Albans,
VT, USA) installed on a computer running Windows XP software.
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Drugs
(±)3,4-methylenedioxypyrovalerone hydrochloride (HCl) (MDPV), (±)-mephedrone HCl,
(+)-methamphetamine HCl, (-)-cocaine HCl, (+)-lysergic acid diethylamide tartrate, and (+)-fenfluramine
HCl were provided by the National Institute on Drug Abuse Drug Control Supply Program (Bethesda, MD,
USA). d-Amphetamine hemisulfate was purchased from Sigma-Aldrich Co. (St. Louis, MO, USA). Each
drug solution was prepared by dissolving salt in 0.9% (wt/vol) bacteriostatic saline. All doses are expressed
as weight of salt. Drug injections were performed via intraperitoneal (ip) injections with a 15-min
pre-session injection interval in a 1ml/kg injection volume.
Operant Training Procedures
All chambers and levers were wiped clean with 35% isopropyl alcohol after every experimental
session to attenuate olfactory cues remaining on the levers and in the testing environment (Extance &
Goudie, 1981). Additionally, on all training and testing days, rats received their daily food rations at
variable intervals post-session (generally 5-10-min post-session) to attenuate post-session suppression of
responding (Smethells, Fox, Andrews, & Reilly, 2012).
Magazine training. All subjects were placed in the operant chambers for a single, 60-min session
where food was delivered under a variable-time 60-s schedule of reinforcement. The criterion for
proceeding to lever press training consisted of each rat consuming all pellets from the magazine by the end
of the 60-min session. All subjects proceeded to lever press training after one session.
Lever press training. After the initial magazine training session, lever press training sessions
began. During lever press training, each rat was placed in an operant chamber with only the center lever
extended. Food deliveries were response-dependent under a fixed-ratio (FR) schedule of reinforcement. All
subjects were required to produce five food pellets under an FR schedule before the FR requirement
increased by one (e.g., five total responses under FR1, followed by five responses under FR2). Lever press
training sessions consisted of five training phases: 1) FR 1-FR 5, 2) FR 5-FR 10, 3) FR 10-FR 15, 4) FR
15-FR 20, and 5) FR 20. Note that each session began with the maximum FR schedule obtained in the
previous session. These sessions were selected to engender reliable lever presses under the terminal FR 20
schedule. In the event a subject did not display reliable responding under a particular FR schedule, the FR
schedule was incrementally reduced until responding occurred again. Each session lasted 30-min or until a

31

subject produced 60 food pellets, whichever occurred first. All subjects proceeded to errorless training after
7-10 lever-press training sessions.
Errorless (single lever) training. During single lever training sessions, rats were injected (ip)
with either drug (D) or vehicle (V) and placed in the chamber with only the condition-appropriate lever
extended. Drug injections consisted of 0.3 mg/kg MDPV (N = 8) or 1.0 mg/kg 4-MMC (N = 8) specific to
the training group, and vehicle injections consisted of 0.9% bacteriostatic saline for both groups. The
assignment of each drug condition on the two levers (i.e., either the left lever or the right lever) was
counterbalanced across half of the subjects within each training drug condition. All rats were exposed to six
errorless training sessions in the following order: V,V,D,D,V,D. Responses were reinforced under an FR 20
schedule. In the event a subject did not reliably respond (i.e., produced few food pellets relative to the other
subjects within the same training group), the FR requirement was incrementally reduced until reliable
responding once again occurred under the FR 20 schedule. All rats were responding on an FR 20 schedule
by the last training session (sixth training session) within each drug condition.
Discrimination training. During discrimination training sessions, rats were injected with either D
or V and placed in the chamber with both levers extended. Drug and vehicle training sessions were
implemented in a pseudorandom order, under the limitation that no animal received more than two
consecutive drug or two consecutive vehicle sessions throughout the study. For example, in any six-day
period, D and V sessions occurred in one of the following orders: VVDDVD, DDVVDV, VDDVDD,
DDVDDV, DVVDDV, or DVDVVD. Consistent with errorless training, lever assignments (either D or V)
remained constant for each rat, and counterbalanced across half of the rats within each training group. The
criteria for discrimination training required rats to emit ≥80% condition-appropriate lever responses prior to
the delivery of the first reinforcer and for the remainder of the training session for at least 8 of 10
consecutive discrimination training sessions.
Stimulus substitution testing. Stimulus substitution tests commenced when each subject met the
criteria for discrimination training above. A test session occurred after a subject completed no less than one
drug training session and one vehicle training session, where in each session it emitted ≥ 80% conditionappropriate responding prior to the first FR and throughout the duration of the session. If a subject did not
meet these criteria, training sessions continued until it met these criteria under each stimulus condition for
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two consecutive sessions. Doses of substitution test compounds were counterbalanced across subjects in
each training group. Substitution tests occurred no more than two times per week with the compounds
presented Table 3:

Table 3
Compounds for Substitution Tests
Test Compound
MDPV HCl
4-MMC HCl
d-Amphetamine hemisulfate
(+)-Methamphetamine HCl
(-)-Cocaine HCl
MDMA HCl
(+)-LSD tartrate
(+)-Fenfluramine HCl
Drugs were tested in the order depicted above.

Dose (mg/kg)
0, 0.01, 0.03, 0.1, 0.3, 1, 3
0, 0.01, 0.03, 0.1, 0.3, 1, 3, 10
0, 0.03, 0.1, 0.3, 1, 3
0.03, 0.1, 0.3, 1, 3
0, 0.1, 0.3, 1, 3, 10
0, 0.03, 0.1, 0.3, 1, 3
0.01, 0.03, 0.1, 0.2
0.03, 0.1, 0.3, 1, 3

During stimulus substitution testing, rats were injected with a dose of one of the following
compounds, returned to their home cages, and placed into the experimental chamber after the 15-min
pre-session injection interval had elapsed. A test session ended after a subject completed 20 consecutive
responses on either lever or 20-min elapsed, whichever occurred first. All test sessions were conducted
under extinction and were treated as a D session (or V session for saline tests). The doses for all
substitution test compounds were taken from previous drug discrimination studies conducted in-house,
which tested the drug in the same species, via the same route of administration (ip).
Data Analysis
Acquisition of drug stimulus control was determined by the number of discrimination training
sessions required to reach criterion among each training group (see above). Learning curves for each
training group were created to display mean percent drug-lever selection during the first FR as a function of
training sessions. Percent drug-lever selection was determined by dividing the number of responses on the
D lever by the total number of responses emitted up to completion of the first FR 20 on either lever.
Nonparametric Kaplan-Meier survival curves were generated to display the number of training sessions
among the two groups. Differences in survival curves were analyzed using a Log-Rank (Mantel-Cox) test.
In addition, an intercorrelation matrix was created to assess the strength of relationships among the
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following set of variables within each training group: injection (1=drug, 0=vehicle), percent drug-lever
selection during the first FR, rate of responding during the first FR, latency to complete the first FR, and
the number of reinforcers (SR+) earned throughout the 20 min session. For the foregoing intercorrelation
matrix, only data recorded during the first 20 training sessions within each training group were used for
analysis.
The lever (i.e., training drug or saline vehicle) on which the first FR 20 was completed, percent
drug-lever responding and responses per second were obtained for each test session. Percent drug-lever
selection and responses per second were reported as means (± SE) in dose-response curves. Full
substitution was considered 80% or greater drug-lever selection, partial substitution was considered greater
than 20% and less than 80% drug-lever selection, and less than 20% drug-lever selection was considered no
substitution. The potencies of MDPV, 4-MMC, d-amphetamine, (+)-methamphetamine, (-)-cocaine,
MDMA, (+)-LSD, or (+)-fenfluramine were determined by effective-dose (ED50) values. ED50 values (with
a range set 0-100%) were calculated by fitting linear functions to the percent drug-lever selection measures
for each compound using a least squares regression analysis. Linear portions of dose-response curves,
including not more than a single dose producing <20% drug-lever selection and not more than a single dose
producing >80% drug-lever selection, were used to compute regression equations. Predicted ED 50 values
were then computed for each test dose-response curve using the calculated regression equations and 95%
confidence intervals were attached to each predicted value. Further, ED50 values were only computed if, in
addition to a substitution test compound producing full substitution, at least six of the eight subjects within
each training group completed the FR 20 on either lever during a test session. For all dose-response curves,
the percent substitution value for the vehicle (V) test was determined by calculating the average of all V
substitution tests obtained in the experiment for each training group (see Table 3). In addition to the
foregoing data analysis that treated the data as graded, data were analyzed as quantal by computing the
percentage of subjects that selected the D lever (i.e., displayed >80% drug-appropriate responding) for each
dose of a test compound (also note that subjects were required to complete FR 20 on either lever to be
included in quantal dose-response calculations). As such, graded and quantal dose-response curves were
plotted into a single graph for visual analysis. Finally, the maximum mean percent substitution values for
each test drug obtained from the 0.3 mg/kg MDPV training group were correlated to the maximum mean
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values for each test drug obtained from the 1.0 mg/kg 4-MMC training group using a Pearson r correlation
analysis.
Response rates were presented as the number of responses emitted per second divided by the total
session time. Response rate data associated with each stimulus substitution test drug were analyzed by
one-way repeated-measures analysis of variance (RMANOVA) followed by Dunnett’s multiple
comparisons tests that compared each dose of a test drug to V. Similar to the percent substitution value for
V, the response rate value for V was determined by calculating the average of all response rate values
obtained during V substitution tests in the experiment for each training group (see Table 3). Statistical
significance was identified at p ≤ .05. Computations of ED50 values, Pearson r correlation, and response
rate data were performed using PRISM GraphPad Version 7 software (La Jolla, CA, USA), and
intercorrelation matrices were constructed using IBM SPSS Version 22 (Armonk, NY, USA). All graphical
displays were created using PRISM GraphPad Version 7 software (La Jolla, CA, USA).

RESULTS
Acquisition of Drug Stimulus Control
A major objective of the present study was to determine if rats could reliably discriminate 0.3
mg/kg MDPV or 1.0 mg/kg 4-MMC from saline. Figure 1 and Figure 2 display the learning curves of two
separate groups of eight rats trained to discriminate 0.3 mg/kg MDPV or 1.0 mg/kg 4-MMC from vehicle,
respectively. Each data point represents the mean (±SE) for each percent drug-lever selection prior to the
delivery of the first reinforcer in rats responding under an FR 20 schedule of food reinforcement. Note in
Figure 1 and Figure 2 that both drug and saline sessions are plotted as percent drug-lever selection. Two
subjects in the 4-MMC training group (Red 2 and Red 5) returned to discrimination training after
displaying poor stimulus generalization in several stimulus substitution tests. As evident in Figures 1 and 2,
as the number of the training sessions continued, the separation between the percent-drug substitution
values (i.e., drug responses appearing above the 80% dashed line) and non-drug responses approaching or
falling below the 20% dashed line become more evident, reflecting the development of drug stimulus
control.
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Figure 1. Learning curve of rats trained to discriminate 0.3 mg/kg MDPV from saline vehicle. Filled circles
(●) represent the effect of 0.3 mg/kg MDPV and open circles (○) represent response of saline vehicle
(means ± SE). After session 20, sample size is less than 8 on some training sessions due to some subjects
having met the discrimination criteria (the number of rats is indicated in parenthesis, otherwise the number
of rats was equal to 8).
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Figure 2. Learning curve of rats trained to discriminate 1.0 mg/kg 4-MMC from saline vehicle. Filled
circles (●) represent the effect of 1.0 mg/kg 4-MMC and open circles (○) represent response of saline
vehicle (means ± SE). After session 20, sample size is less than 8 on some training sessions due to some
subjects having met the discrimination criteria (the number of rats is indicated in parenthesis, otherwise the
number of rats was equal to 8).
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Figure 3 displays a survival plot depicting when each rat reached acquisition training criteria
within each training group. The 0.3 mg/kg MDPV training group met the training criteria in an average of
35.38 sessions (SD = 13.5), and the 1.0 mg/kg 4-MMC training group met the training criteria in an
average of 37.40 sessions (SD = 16). As mentioned above, two subjects in the 4-MMC training group
returned to discrimination training following a few substitution tests wherein poor drug stimulus control
over responding was evident (i.e., inconsistent percent drug-lever selection across training sessions and
substitution test sessions). As such, the survival plot below, but not the foregoing 4-MMC group learning
curve, includes the additional discrimination training sessions required for one of these two subjects. A
Log-Rank (Mantel-Cox) test performed on the survival curves in Figure 3 revealed no difference in the
number of training sessions required to reach criteria between the MDPV and 4-MMC training drug
groups, [χ2(1) = 0.05, p > .05].

Figure 3. Nonparametric Kaplan-Meier survival curves (± 95% confidence interval [CI]) displaying the
number of training sessions required for each training group to reach training criteria (note the scale break
along the abscissa). The smaller, dotted black lines above and below the survival curves represent the CI
for the MDPV training group; the smaller, dotted grey lines above and below the survival curves represent
the CI for the 4-MMC training group. A vertical increase capped with a solid rectangle indicates a subject
reaching criterion in the associated training group.
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Supplementary Training Dependent Measures
Tables 4 and 5 present the intercorrelation matrices for the 0.3 mg/kg MDPV and 1.0 mg/kg
4-MMC training groups, respectively. In the 0.3 mg/kg MDPV training group, only data collected from 19
of the 20 training sessions were used in constructing the intercorrelation matrix because on one occasion
two subjects failed to complete an FR during the entire 20 min training session. As such, the variables
recorded during that session were omitted from the analysis to reduce the effects of outliers on the strength
of the correlations (i.e., the effects of the deviant latency to complete first FR values). Nevertheless, in the
0.3 mg/kg MPDV-trained rats, statistically significant positive correlations were observed among the
injection and percent, and SR+ and percent variables; significant negative correlations were observed
among the injection and rate, latency and percent, and SR+ and latency variables. In the 1.0 mg/kg
4-MMC-trained rats, statistically significant positive correlations were observed among the SR+ and
percent, and SR+ and rate variables; significant negative correlations were observed among the SR+ and
latency variables.

Table 4
Intercorrelation Matrix of Variables in 0.3 mg/kg MDPV Training Group
Injection
Injection
Percent (1st FR)
Rate (1st FR)
Latency (1st FR)
SR+
** p < .012-tail

1
.703**
-.615**
-.248
.311

Percent (1st FR)
1
-.373
-.703**
.640**

Rate (1st FR)

1
-.125
.143

Latency (1st FR)

SR+

1
-.821**

1

Table 5
Intercorrelation Matrix of Variables in 1.0 mg/kg 4-MMC Training Group
Injection
1
Injection
.431
Percent (1st FR)
-.006
Rate (1st FR)
.061
Latency (1st FR)
.202
SR+
*p < .052-tail **p < .012-tail

Percent (1st FR)
1
.255
-.729**
.695**

Rate (1st FR)

1
-.368
.525*

Latency (1st FR)

1
-.798**

SR+

1
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Substitution Tests
Individual dose-response curves generated from substitution tests are grouped together in Figures
4 through 7 based on similar pharmacological effects. However, it should be noted that the presentation
order of these figures does not coincide with the order in which the subjects received the test drug
compounds. The substitution test order is indicated in Table 3 within the Methods.
0.3 mg/kg MDPV training group
MDPV. The percent MDPV-lever selection and response rates under MDPV (0.01 – 0.3 mg/kg)
are displayed in Figure 4A. MDPV dose-dependently increased MDPV-lever selection up to the 0.3 mg/kg
training dose, which was the only dose to produce full substitution (100% ± 0 SE) (ED50 = 0.06 mg/kg;
95% Confidence Interval [CI] = 0.03 – 0.11 mg/kg). A RMANOVA revealed a statistically significant
effect of MDPV on responses per second [F(4, 28) = 3.06, p = .03, η2 = 0.18]. Dunnett’s multiple
comparisons tests failed to detect where the statistical differences occurred among the response rate values.
d-Amphetamine. The percent MDPV-lever selection and response rates under d-amphetamine
(0.03 – 1.0 mg/kg) are displayed in Figure 4B. d-Amphetamine dose-dependently increased MDPV-lever
selection up to the 1.0 mg/kg dose. Both the 0.3 (80.46% ± 12.84) and 1.0 (100% ± 0) doses of
d-amphetamine fully substituted for 0.3 mg/kg MDPV (ED50 = 0.14 mg/kg; 95% CI = 0.08 – 0.24 mg/kg).
A RMANOVA failed to reveal a statistically significant effect of d-amphetamine on responses per second
[F(4, 28) = 2.34, p = .08].
(+)-Methamphetamine. The percent MDPV-lever selection and response rates under
(+)-methamphetamine (0.03 – 1.0 mg/kg) are displayed in Figure 4C. (+)-Methamphetamine
dose-dependently increased MDPV-lever selection up to the 1.0 mg/kg (+)-methamphetamine dose. Both
the 0.3 (86.87% ± 11.22) and 1.0 (97.86% ± 2.14) doses of methamphetamine fully substituted for 0.3
mg/kg MDPV (ED50 = 0.12 mg/kg; 95% CI = 0.07 – 0.22 mg/kg). A RMANOVA failed to reveal a
statistically significant effect of methamphetamine on responses per second [F(4, 28) = 2.59, p = .058].
(-)-Cocaine. The percent MDPV-lever selection and response rates under (-)-cocaine (0.1 - 10
mg/kg) are displayed in Figure 4D. Cocaine dose-dependently increased MDPV-lever selection up to the 10
mg/kg cocaine dose, which was the only dose to fully substitute for 0.3 mg/kg MDPV (ED50 = 0.73 mg/kg;

40

95% CI = 0.37 – 1.47 mg/kg). A RMANOVA failed to reveal a statistically significant effect of cocaine on
responses per second [F(5, 35) = 1.129, p = .36].

Figure 4. Results of substitution tests with doses of (A) MDPV, (B) d-amphetamine, (C)
(+)-methamphetamine, and (D) (-)-cocaine in rats trained to discriminate 0.3 mg/kg MDPV from saline.
Mean (±SE) percent MDPV-lever selection (left ordinate) and mean (±SE) responses per second (right
ordinate).
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Figure 5 presents a comparison between the foregoing graded dose-response curves for MDPV,
d-amphetamine, (+)-methamphetamine, and (-)-cocaine to the same dose-response curves analyzed under a
quantal approach, in rats trained to discriminate 0.3 mg/kg MDPV from saline. Note the similarity of the
dose-response curves obtained between the percent MDPV-lever selection metric (graded) and the percent
subjects selecting MDPV lever metric (quantal).

Figure 5. Quantal and graded results of substitution tests with doses of (A) MDPV, (B) d-amphetamine, (C)
(+)-methamphetamine, and (D) (-)-cocaine in rats trained to discriminate 0.3 mg/kg MDPV from saline.
Mean percent MDPV-lever selection (●, graded, left ordinate) and percent subjects selecting MDPV lever
(■, quantal, right ordinate).
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4-MMC. The percent MDPV-lever selection and response rates under 4-MMC (0.03 - 10.0
mg/kg) are displayed in Figure 6A. 4-MMC dose-dependently increased MDPV-lever selection with the 10
mg/kg dose (n = 6) producing partial substitution (77.26% ± 12.46). Higher doses of 4-MMC were not
tested. A RMANOVA revealed a statistically significant main effect of 4-MMC on responses per second
[F(6, 42) = 15.22, p < .0001, η2 = 0.49]. Dunnett’s multiple comparisons tests revealed that the 3 and 10
mg/kg doses of 4-MMC produced decreases in responses per second compared to V.
MDMA. The percent MDPV-lever selection and response rates under MDMA (0.1 – 3.0 mg/kg)
are displayed in Figure 6B. MDMA did not produce notable dose-dependent increases on MDPV-lever
selection, and the highest dose tested, 3 mg/kg MDMA (n = 7), only produced low partial substitution
(26.62% ± 14.52). A RMANOVA revealed a statistically significant effect of MDMA on responses per
second [F(4, 28) = 5.57, p = .002, η2 = 0.25]. Dunnett’s multiple comparisons tests revealed that the 3
mg/kg dose of MDMA produced decreases in responses per second compared to V.
(+)-LSD. The percent MDPV-lever selection and response rates under (+)-LSD (0.01 – 0.1 mg/kg)
are displayed in Figure 6C. LSD did not produce noteworthy dose-dependent increases on MDPV-lever
selection, and the highest dose tested, 0.1 mg/kg LSD (n = 7), only produced low partial substitution
(28.80% ± 15.01). A RMANOVA failed to reveal a statistically significant effect of LSD on responses per
second [F(3, 21) = 2.40, p = .10].
(+)-Fenfluramine. The percent MDPV-lever selection and response rates under (+)-fenfluramine
(0.03 – 3 mg/kg) are displayed in Figure 6D. Percent MDPV-lever selection values remained low among
the three lowest doses of fenfluramine tested (0.1 – 1 mg/kg), however 3 mg/kg fenfluramine produced full
substitution in four of the eight rats (89.88 ± 10.12). A RMANOVA revealed a statistically significant
effect of fenfluramine on responses per second [F(5, 35) = 6.28, p = < .001, η2 = 0.37]. Dunnett’s multiple
comparisons tests revealed that the 0.03 and 3 mg/kg doses of fenfluramine each produced decreases in
response rates compared to V.
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Figure 6. Results of substitution tests with doses of (A) 4-MMC, (B) MDMA, (C) (+)-LSD, and (D)
(+)-fenfluramine in rats trained to discriminate 0.3 mg/kg MDPV from saline. Mean (±SE) percent
MDPV-lever selection (left ordinate) and mean (±SE) responses per second (right ordinate). Rats that did
not complete FR during a test session were not included in the percent drug-lever selection data (the
number of rats is indicated in parenthesis, otherwise the number of rats was equal to 8). For the response
rate data, statistical differences from V are indicated by asterisks (**p < .01 ****p < .0001).
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Figure 7 presents a comparison between the foregoing graded dose-response curves for 4-MMC,
MDMA, (+)-LSD, and (+)-fenfluramine to the same dose-response curves analyzed under a quantal
approach, in rats trained to discriminate 0.3 mg/kg MDPV from saline. Similar to Figure 5 above, note the
resemblance of the dose-response curves obtained between the percent MDPV-lever selection metric
(graded) and the percent subjects selecting MDPV lever metric (quantal).

Figure 7. Quantal and graded results of substitution tests with doses of (A) 4-MMC, (B) MDMA, (C)
(+)-LSD, and (D) (+)-fenfluramine in rats trained to discriminate 0.3 mg/kg MDPV from saline. Mean
percent MDPV-lever selection (●, graded, left ordinate) and percent subjects selecting MDPV lever (■,
quantal, right ordinate). Rats that did not complete FR during a test session were not included (the number
of rats is indicated in parenthesis, otherwise the number of rats was equal to 8).

45

The foregoing substitution test results obtained in the 0.3 mg/kg MDPV-trained rats are
summarized in Table 6 below.

Table 6
Summary of Substitution Test Data in 0.3 mg/kg MDPV Training Group
Mean Maximum Percent Substitution ± SE ED50 (mg/kg)
95% CI (mg/kg)
MDPVa
100 ± 0
0.06
0.03 – 0.11e
b
4-MMC
77.26 ± 12.46
--------AMPc
100 ± 0
0.14
0.08 – 0.24e
METHd
97.86 ± 2.14
0.12
0.07 – 0.22e
COCe
97.92 ± 2.08
0.73
0.37 – 1.47acd
MDMAf
27.24 ± 16.71
--------LSDg
28.80 ± 15.01
--------FENh
89.88 ± 10.12*
--------A letter superscript indicates non-overlapping 95% CIs between two test compounds where applicable, and
an asterisk superscript indicates that less than six subjects’ substitution test results were used to calculate
the associated mean maximum percent substitution value, precluding ED50 determination. Abbreviations:
3,4-methylenedioxypyrovalerone (MDPV), 4-methylmethcathinone (4-MMC), d-amphetamine (AMP),
(+)-methamphetamine (METH), (-)-cocaine (COC), 3,4-methylenedioxymethamphetamine (MDMA),
(+)-lysergic acid diethylamide (LSD), and (+)-fenfluramine (FEN).

1.0 mg/kg 4-MMC training group
4-MMC. The percent 4-MMC-lever selection and response rates under 4-MMC (0.01 - 1 mg/kg)
are displayed in Figure 8A. 4-MMC dose-dependently increased 4-MMC-lever selection up to the 1.0
mg/kg training dose, which was the only dose to produce full substitution (96.19% ± 2.18) (ED50 = 0.18
mg/kg; 95% CI = 0.08 – 0.38 mg/kg). A one-way repeated-measures ANOVA (RMANOVA) failed to
reveal a statistically significant effect of 4-MMC on responses per second [F(5, 35) = 0.9917, p = .44].
MDMA. The percent 4-MMC-lever selection and response rates under MDMA (0.01 - 1 mg/kg)
are displayed in Figure 8B. MDMA dose-dependently increased 4-MMC-lever selection up to 1.0 mg/kg,
which was the only dose to fully substitute for 1.0 mg/kg 4-MMC (96.34% ± 2.05) (ED50 = 0.16 mg/kg;
95% CI = 0.08 – 0.36 mg/kg). A RMANOVA failed to reveal a statistically significant effect of MDMA on
responses per second [F(4, 28) = 1.627, p = .20].
(+)-LSD. The percent 4-MMC-lever selection and response rates under (+)-LSD (0.01 – 0.2
mg/kg) are displayed in Figure 8C. LSD dose-dependently increased 4-MMC-lever selection up to the 0.1
mg/kg LSD dose (49.22% ± 14.73) (n =7), but decreased 4-MMC-lever selection at the 0.2 mg/kg LSD
dose (32.16% ± 3.13) (n = 2). A RMANOVA revealed a statistically significant effect of LSD on responses
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per second [F(4, 28) = 19.68, p = <.0001, η2 = 0.66]. Dunnett’s multiple comparisons tests revealed that the
0.1 and 0.2 mg/kg doses of LSD produced decreases in response rate compared to V.
(+)-Fenfluramine. The percent 4-MMC-lever selection and response rates under (+)-fenfluramine
(0.1 - 3 mg/kg) are displayed in Figure 8D. Fenfluramine dose-dependently increased 4-MMC-lever
selection and produced partial substitution at 3 mg/kg (74.32% ± 15.67) (n =6). A RMANOVA revealed a
statistically significant effect of fenfluramine on responses per second [F(4, 28) = 9.12, p = <.0001, η2 =
0.47]. Dunnett’s multiple comparisons tests revealed that the 0.3, 1, and 3 mg/kg doses of fenfluramine
produced decreases in response rate compared to V.
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Figure 8. Results of substitution tests with doses of (A) 4-MMC, (B) MDMA, (C) (+)-LSD, and (D)
(+)-fenfluramine in rats trained to discriminate 1.0 mg/kg 4-MMC from saline. Mean (±SE) percent
MDPV-lever selection (left ordinate) and mean (±SE) responses per second (right ordinate). Rats that did
not complete FR during a test session were not included in the percent drug-lever selection data (the
number of rats is indicated in parenthesis, otherwise the number of rats was equal to 8). For the response
rate data, statistical differences from V are indicated by asterisks (*p <.05, **p < .01, ***p <.001, ****p <
.0001).
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Figure 9 presents a comparison between the foregoing graded dose-response curves for 4-MMC,
MDMA, (+)-LSD, and (+)-fenfluramine to the same dose-response curves analyzed under a quantal
approach, in rats trained to discriminate 1.0 mg/kg 4-MMC from saline. Aside from the slight discrepancies
in percent substitution among the 4-MMC and (+)-LSD curves, it appears that the graded and quantal
approaches produced comparable dose-effect functions.

Figure 9. Quantal and graded results of substitution tests with doses of (A) 4-MMC, (B) MDMA, (C)
(+)-LSD, and (D) (+)-fenfluramine in rats trained to discriminate 1.0 mg/kg 4-MMC from saline. Mean
percent 4-MMC-lever selection (●, graded, left ordinate) and percent subjects selecting 4-MMC lever (■,
quantal, right ordinate). Rats that did not complete FR during a test session were not included (the number
of rats is indicated in parenthesis, otherwise the number of rats was equal to 8).
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MDPV. The percent 4-MMC-lever selection and response rates under MDPV (0.03 – 3 mg/kg) are
displayed in Figure 10A. MDPV dose-dependently increased 4-MMC-lever selection up to 3 mg/kg (n = 7),
which was the only dose to fully substitute for 1.0 mg/kg 4-MMC (85.12% ± 13.49) (ED50 = 0.63 mg/kg;
95% CI = 0.31 – 1.30 mg/kg). A RMANOVA revealed a statistically significant effect of MDPV on
responses per second [F(5, 35) = 4.89, p = .0017, η2 = 0.35]. Dunnett’s multiple comparisons tests revealed
that the 1 and 3 mg/kg doses of MDPV produced decreases in response rate compared to V.
d-Amphetamine. The percent 4-MMC-lever selection and response rates under d-amphetamine
(0.03 – 1 mg/kg) are displayed in Figure 10B. d-Amphetamine dose-dependently increased 4-MMC-lever
selection up to the 1 mg/kg, which was the only dose to fully substitute for 1.0 mg/kg 4-MMC (81.47% ±
13.50) (ED50 = 0.48 mg/kg; 95% CI = 0.26 – 0.89 mg/kg). A RMANOVA failed to reveal a statistically
significant effect of d-amphetamine on responses per second [F(4, 28) = 2.67, p = .052].
(+)-Methamphetamine. The percent 4-MMC-lever selection and response rates under
(+)-methamphetamine (0.03 – 3 mg/kg) are displayed in Figure 10C. (+)-Methamphetamine
dose-dependently increased 4-MMC-lever selection up to 3 mg/kg (n = 3), which was the only dose to fully
substitute for 1.0 mg/kg 4-MMC (100% ± 0). An ED50 value was not computed for this test compound
since only three out of the eight subjects responded under the highest tested dose. A RMANOVA revealed
a statistically significant effect of responses per second [F(5, 35) = 10.32, p < .0001, η2 = 0.47]. Dunnett’s
multiple comparisons tests revealed that the 3 mg/kg dose of methamphetamine produced decreases in
responses per second compared to V.
(-)-Cocaine. The percent 4-MMC-lever selection and response rates under (-)-cocaine (0.03 - 10
mg/kg) are displayed in Figure 10D. Cocaine dose-dependently increased 4-MMC-lever selection up to 10
mg/kg, which was the only dose to fully substitute for 1.0 mg/kg 4-MMC (98.09% ± 1.36) (ED50 = 0.92
mg/kg; 95% CI = 0.34 – 2.08 mg/kg). A RMANOVA failed to reveal a statistically significant effect of
cocaine on responses per second [F(5, 35) = 1.81, p = .14].
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Figure 10. Results of substitution tests with doses of (A) MDPV, (B) d-amphetamine, (C)
(+)-methamphetamine, and (D) (-)-cocaine in rats trained to discriminate 1.0 mg/kg 4-MMC from saline.
Mean (±SE) percent 4-MMC-lever selection (left ordinate) and mean (±SE) responses per second (right
ordinate). Rats that did not complete FR during a test session were not included in the percent drug-lever
selection data (the number of rats is indicated in parenthesis, otherwise the number of rats was equal to 8).
For the response rate data, statistical differences from V are indicated by asterisks (*p < .05; **p < .01;
****p < .0001).
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Figure 11 presents a comparison between the foregoing graded dose-response curves for MDPV,
d-amphetamine, (+)-methamphetamine, and (-)-cocaine to the same dose-response curves analyzed under a
quantal approach, in rats trained to discriminate 1.0 mg/kg 4-MMC from saline.

Figure 11. Quantal and graded results of substitution tests with doses of (A) MDPV, (B) d-amphetamine,
(C) (+)-methamphetamine, and (D) (-)-cocaine in rats trained to discriminate 1.0 mg/kg 4-MMC from
saline. Mean percent 4-MMC-lever selection (●, graded, left ordinate) and percent subjects selecting
4-MMC lever (■, quantal, right ordinate). Rats that did not complete FR during a test session were not
included (the number of rats is indicated in parenthesis, otherwise the number of rats was equal to 8).
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The foregoing substitution test results obtained in the 1.0 mg/kg 4-MMC trained rats are
summarized in Table 7 below.

Table 7
Summary of Substitution Test Data in 1.0 mg/kg 4-MMC Group
Mean Maximum Percent Substitution ± SE ED50 (mg/kg)
95% CI (mg/kg)
4-MMCa
96.19 ± 2.18
0.18
(0.08 – 0.38)
MDPVb
85.12 ± 13.49
0.63
(0.31 – 1.30)
AMPc
81.47 ± 13.50
0.48
(0.26 – 0.89)
METHd
100 ± 0*
--------COCe
98.09 ± 1.36
0.92
(0.34 – 2.08)
MDMAf
96.34 ± 2.05
0.16
(0.08 – 0.36)
LSDg
49.22 ± 14.73
--------FENh
78.08 ± 13.33
--------An asterisk superscript indicates that less than six subjects’ substitution test results were used to calculate
the associated mean maximum percent substitution value, precluding ED50 determination. Abbreviations:
3,4-methylenedioxypyrovalerone (MDPV), 4-methylmethcathinone (4-MMC), d-amphetamine (AMP),
(+)-methamphetamine (METH), (-)-cocaine (COC), 3,4-methylenedioxymethamphetamine (MDMA),
(+)-lysergic acid diethylamide (LSD), and (+)-fenfluramine (FEN).

Relationship between 0.3 mg/kg MDPV and 1.0 mg/kg 4-MMC Cues
Figure 12 presents the mean maximum percent drug-lever selection values of the substitution test
compounds and averaged vehicle test values obtained in the 0.3 mg/kg MDPV training group (see Table 6)
plotted as a function of the same values obtained in the 1.0 mg/kg 4-MMC training group (see Table 7).
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Figure 12. Percent drug-lever selection data from the present experiment are summarized for several
substitution test compounds tested in one group of rats trained to discriminate 0.3 mg/kg MDPV from
vehicle and in another group of rats trained to discriminate 1.0 mg/kg 4-MMC from vehicle. The highest
percent of percent 4-MMC-lever selection is shown on the ordinate as a function of the highest percent
MDPV-lever selection for each drug on the abscissa. A rectilinear regression line for the data and the
Pearson r correlation coefficient are also displayed. Note: the sample sizes for each data point are
consistent with the number of rats that completed the FR 20 for each substitution test compound.
Abbreviations: V (vehicle), 3,4-methylenedioxypyrovalerone (MDPV), 4-methylmethcathinone (4-MMC),
d-amphetamine (AMP), (+)-methamphetamine (METH), (-)-cocaine (COC),
3,4-methylenedioxymethamphetamine (MDMA), (+)-lysergic acid diethylamide (LSD), and
(+)-fenfluramine (FEN).
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DISCUSSION

Discriminative stimulus control by 0.3 mg/kg MDPV or 1.0 mg/kg 4-MMC was established within
an average of ~35 and ~37 discrimination training sessions, respectively, although it is noteworthy that two
of the subjects in the 4-MMC training group required remedial training sessions. These results demonstrate
that 0.3 mg/kg MDPV and 1.0 mg/kg 4-MMC can serve as antecedent sources of control over lever-press
responding in rats. As evidenced by comparable survival curves that display acquisition of discrimination
as a function of training sessions, the selected training doses of MDPV and 4-MMC appear to have served
as equieffective, salient discriminative cues under these testing conditions.
Inspection of individual subject performance in the percent drug-substitution measure (see
Appendices A and B) reveals that in most testing sessions, subjects responded in an all-or-none fashion.
That is, most subjects dose-dependently responded <20% or >80% under the substitution test compounds.
Such responding is often considered characteristic of quantal performance—either the test drug cue
resembles the training drug cue, or it does not. This type of responding can be contrasted with graded
responding that is characterized by subjects’ percent drug-lever selection values appearing proportional to
increases in dose of a drug. Regardless of whether individual subject performance appears quantal, early
behavioral research on conditional discrimination supports the notion that group or collated behavioral
performances that appear graded are often the result of averaging individuals’ quantal responses (e.g.,
Sidman, 1980; Bickel & Etzel, 1985).
Much of the discussion of graded versus quantal responding is due to interpretation issues
associated with partial substitution percent drug-lever selection data (i.e., percent drug-lever selection
values that fall between 20-80%). Previous reports have extensively discussed relationships between
procedural variables (e.g., schedule of reinforcement, training dose) and relevant data outcomes, such as
maximum discrimination accuracy and response rates (e.g., Overton, 1979; Stolerman & D’Mello, 1981;
Stolerman, 1991). In light of the foregoing discussion on quantal and graded responding, it is noteworthy
that previous research has demonstrated that the type of percent substitution data observed (i.e., graded or
quantal) may be influenced by the programmed schedule of reinforcement. For example, McMillan, Li, and
Hardwick (2001) trained pigeons to discriminate among 5 mg/kg pentobarbital, 5 mg/kg morphine, and
saline under an FR 20 schedule or an FI 90-s schedule. The results of that study revealed that responding
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under the FR 20 schedule generated quantal-like dose-response curves and those responding under the FI
90-s schedule generated graded-like dose-response curves (McMillan, Li, & Hardwick, 2001). Similar
findings have been demonstrated elsewhere (e.g., Stolerman, 1989; Barrett, Caul, Huffman, & Smith, 1994;
McMillan, Hardwick, & Li, 2001). In the present study, subjects were trained to respond under an FR 20
schedule of food reinforcement and, given that most recent DD studies completed in the WMU laboratory
have included FR 20 schedules of food reinforcement, individual subjects have consistently displayed
quantal-like responding under a variety of experimental conditions and substitution test compounds
(Berquist and Baker, unpublished observations). Though beyond the scope of the present document to fully
review the debate of quantal versus graded responding (for additional discussion, see Williams, 1987;
Gauvin & Young, 1987; Mathis, Emmett-Oglesby, Harris, & Lal, 1987; Weiss & Schindler, 1987; Bickel,
1987; Barrett, Caul, Huffman, & Smith, 1994; Emmett-Oglesby, 1994; Gauvin & Holloway, 1994), some
have argued that DD methods that generally yield quantal data ought to be abandoned (e.g., Overton,
1994), and others have used other procedures (e.g., conditioned taste aversion preparations) that more
approximate graded responding (e.g., Mathis & Emmett-Oglesby, 1990; Riley et al., 1991).
Despite the theoretical disagreements that exist in interpreting partial percent drug substitution
values, some evidence suggests that data path analyses, and thus determination of drug potency values,
maximal effects (efficacy), etc., are not changed in any appreciable way under the graded and quantal
methods. For example, Schechter (1997a) trained two separate groups of rats to discriminate 10 mg/kg
cocaine or 2 mg/kg MDMA from saline. The training drugs were tested in each group of rats and the
percent drug-lever selection values were separately analyzed as quantal and quantitative (graded) data. In
both training groups, almost identical dose-response curves and ED50 values were obtained using the two
data path analyses. As such, Schechter (1997a) suggested that analyses of quantal and graded data produce
equivalent assessments of the percent drug-lever selection values. Direct comparisons of graded versus
quantal dose-response determinations in the present study (see Figures 5, 7, 9, and 11) support this
conclusion; although, some inconsistencies were observed at specific doses of test compounds in the
present experiment. Similar comparisons and findings between quantal dose-response curves and graded
dose-response curves obtained from subjects trained to discriminate 0.4 mg/kg d-amphetamine or 0.7
mg/kg norfenfluramine from saline have been reported as well (e.g., Schechter, 1997b). Moreover, in some
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cases the schedule of reinforcement does not produce notable differences in stimulus generalization
gradients, but may affect other variables included in the experiment, such as discrimination acquisition. For
example, Kueh and Baker (2007) trained groups of rats to discriminate 1.5 mg/kg MDMA or 10 mg/kg
cocaine from saline under an FR 20 or VI 15-s schedule of food reinforcement. The results of that study
revealed negligible differences in percent drug-lever selection values of substitution test compounds
between rats responding under the two schedules in each training drug group, however, the FR 20-trained
rats in both groups acquired the discrimination more rapidly during training. These results are consistent
with previous research demonstrating that schedule of reinforcement effects influence drug stimulus control
(McMillan & Wenger, 1984; De Vry, Koek, & Slangen, 1984; Snodgrass & McMillan, 1991; Craft,
Morgan, & Bernal, 1998).
The monoamine transporter blockers (MDPV, (-)-cocaine), DA releasers (d-amphetamine,
methamphetamine), and a serotonin releaser ((+)-fenfluramine; in half of the sample) produced full
substitution for the 0.3 mg/kg MDPV cue. Contrariwise, substrates for the monoamine transporters
(4-MMC, MDMA) and a classic serotonergic hallucinogen ((+)-LSD) did not produce full substitution,
although the 10 mg/kg 4-MMC dose produced a high partial substitution value (~78% 4-MMC-lever
selection). These data are partially consistent with a previous study that trained mice to discriminate 0.3
mg/kg MDPV from saline (Fantegrossi, Gannon, Zimmerman, & Rice, 2013). Fantegrossi, Gannon,
Zimmerman, and Rice (2013) reported in 0.3 mg/kg MDPV-trained mice that MDPV, methamphetamine,
and MDMA produced full substitution, whereas the cannabinoid CB1 and CB2 receptor agonist, JWH-018,
and an opioid agonist, morphine, failed to produce full substitution. There exist numerous differences
between the present study and that of Fantegrossi et al. that may account for the discrepant substitution
profile with MDMA. Specifically, the present study trained Sprague-Dawley rats to discriminate 0.3 mg/kg
MDPV from saline under an FR 20 schedule of food reinforcement, with a 15-min pre-session injection
interval, and included discrete-dosing, extinction sessions to test the substitution test compounds.
Contrariwise, Fantegrossi et al. trained NIH Swiss mice to discriminate 0.3 mg/kg MDPV from saline
under an FR 10 -10-s time-out schedule of sweetened milk reinforcement, with a 10-min pre-session
injection interval, and used cumulative-dosing, extinction sessions to test the substitution test compounds.
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As mentioned, only a single report has been published that included a dose of MDPV as the
training drug in a DD procedure (Fantegrossi, Gannon, Zimmerman, & Rice, 2013), precluding thorough
comparisons of the results obtained in the present study. Nevertheless, because MDPV is
pharmacologically similar to cocaine, albeit more potent, it is possible that MDPV may share a similar
substitution profile to MDMA, comparable to the similarities between cocaine and MDMA. For example,
Khorana, Pullagurla, Young, and Glennon (2004) reported that in Sprague-Dawley rats trained to
discriminate 1.5 mg/kg MDMA from saline, cocaine fully substituted for the MDMA cue. In contrast, in
Sprague-Dawley rats trained to discriminate 8 mg/kg cocaine from saline, racemic MDMA, S(+)-MDMA,
and R(-)-MDMA all failed to produce complete generalization. These findings indicate the substitution
profile between MDMA and cocaine is asymmetrical. In contrast, Broadbent, Michael, and Appel (1989)
trained groups of rats to discriminate 3.5, 10, or 20 mg/kg cocaine from saline, and found that the
(l)-MDMA isomer only generalized in 3 out of 5 of the 20 mg/kg cocaine-trained rats. Thus, the training
dose of cocaine likely influences subsequent percent drug-lever selection values with substrates for
monoamine transporters (also, see Schechter, 1997c). It is possible that MDMA would produce complete
generalization in rats trained to discriminate a different dose of MDPV than the 0.3 mg/kg MDPV dose
used in the present experiment, as previous research suggests that the MDMA cue may become more
dopaminergic-mediated as the dose increases (e.g., Harper, Langen, & Schenk, 2014).
Harvey and Baker (2016) trained rats to discriminate 1.5 mg/kg MDMA or a 0.5 mg/kg
d-amphetamine + 1.5 mg/kg MDMA mixture. Interestingly, cocaine, d-amphetamine, and MDPV produced
full substitution for the d-amphetamine + MDMA cue, but not for the MDMA-only cue, whereas MDMA
and 4-MMC fully substituted in for both training cues. These findings suggest that the DA-releasing effects
of 0.5 mg/kg d-amphetamine added to the 1.5 mg/kg MDMA cue were necessary for subjects to display
complete stimulus generalization when tested with monoamine transporter blockers and a DA releaser. In
contrast, d-amphetamine, methamphetamine (in 3 out of 8 subjects), MDPV, and cocaine produced full
substitution in 1 mg/kg 4-MMC-trained rats in the present study. Although previous reports have
demonstrated that 4-MMC produces neurochemical effects that are similar to MDMA (e.g., Kehr et al.
2011; Baumann et al., 2012; Pfil, Reither, & Hornykiewicz, 2015), it is presently unclear why the
aforementioned drugs fully substituted in the 1 mg/kg 4-MMC-trained subjects, but d-amphetamine and
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cocaine did not produce full substitution in the 1.5 mg/kg MDMA-trained subjects used in the study
reported by Harvey and Baker (2016). Possible reasons for such findings may be that, similar to the
foregoing relationship between MDMA and cocaine, substitution effects may be asymmetrical between
MDMA and 4-MMC, or a different training dose of MDMA would be necessary for DA releasers and
monoamine transporter blockers to fully substitute.
In addition to a potential asymmetric substitution profile between MDPV and MDMA, the
discrepant substitution results with MDMA in the present study compared to that reported by Fantegrossi,
Gannon, Zimmerman, and Rice (2013) could be due to different testing procedures. Specifically,
Fantegrossi et al. used cumulative-dosing testing sessions and the present study used discrete-dosing testing
sessions. However, previous research directly comparing cumulative-dosing testing to discrete-dosing
session testing suggests that it is unlikely that the discrepant MDMA substitution tests results are due to
these procedural differences. For example, Schechter (1997a) trained groups of rats to discriminate 10
mg/kg cocaine from saline or 2 mg/kg MDMA from saline. Subgroups within each of the training groups
were exposed to cumulative-dosing testing procedures or discrete-dosing testing sessions. The results of
that study revealed no difference in the training drugs’ dose-response curves or ED50 values.
As a final point, species differences may account for the variant effects of MDMA on MDPV
percent-lever selection between the present study and that of Fantegrossi, Gannon, Zimmerman, and Rice
(2013), however, additional DD studies directly comparing the species under identical procedures would be
necessary to evaluate this speculation. There are currently no known DD studies that have directly
compared the generalization gradients determined from mice and rats, although it is worth noting that
S(+)-amphetamine and cocaine fully-substituted for a 1.5 mg/kg S(+)-MDMA cue in mice (effects that are
similar to the foregoing DD studies using rats), but not for a 1.5 mg/kg R(-)-MDMA cue in a different
group of mice (Murane, Murai, Howell, & Fantegrossi, 2009), suggesting apparent differences in
interoceptive effects elicited by MDMA enantiomers. Moreover, previous research has observed
comparatively greater neurotoxic effects of MDMA on dopaminergic functioning in mice relative to rats,
and greater neurotoxic effects of MDMA on serotonin functioning in rats relative to mice (for review,
Easton & Marsden, 2006). Thus, it is possible that drugs that increase extracellular monoamine levels may
differentially affect discriminative stimulus effects between mice and rats.
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Despite the discrepant substitution results observed with MDMA between the present study and
the Fantegrossi, Gannon, Zimmerman, and Rice (2013) study, MDPV and methamphetamine displayed full
substitution in both studies. Moreover, the ED50 values are somewhat comparable between these studies
(present study ED50 values, expressed in mg/kg: MDPV = 0.06; methamphetamine = 0.12; Fantegrossi et
al. (2013) ED50 values: MDPV = 0.03; methamphetamine = 0.08); although, for both MDPV and
methamphetamine in Fantegrossi et al., the observed potency values were lower. Such differences between
the estimated ED50 values may be due to the aforementioned species differences (i.e., mice may be more
sensitive than rats to the effects of increased extracellular dopamine).
As mentioned, MDMA and 4-MMC failed to produce complete generalization in 0.3 mg/kg
MDPV-trained rats in the present study, however 4-MMC approached full substitution at the highest dose
tested. Although only a single DD study has been published using a dose of MDPV as the training drug
(Fantegrossi, Gannon, Zimmerman, & Rice, 2013), other studies have tested 4-MMC for substitution in rats
trained to discriminate a DA releaser, methamphetamine, or a monoamine transporter blocker, cocaine,
from saline. For example, Gatch, Taylor, and Forster (2013) trained groups of rats to discriminate 1 mg/kg
methamphetamine or 10 mg/kg cocaine from saline and tested 4-MMC for substitution. In that study,
4-MMC equipotently produced full substitution for both training drug cues. It is noteworthy that Gatch et
al. used an approximately 33 fold higher dose of cocaine (10 mg/kg) for training than the dose used for
MDPV (0.3 mg/kg) in the present study. Previous research has demonstrated that MDPV is ~10 times more
potent than cocaine at producing locomotor activation (e.g., Baumann et al., 2013), comparison of the ED50
values of MDPV (ED50 = 0.06 mg/kg) and (-)-cocaine (ED50 = 0.73 mg/kg) obtained in the present study
reveals that MDPV is approximately 12 times more potent than (-)-cocaine at producing the 0.3 mg/kg
MDPV cue, a relative potency difference that appears consistent with that reported by Baumann et al.
(2013). In any event, future studies including a higher training dose of MDPV may be necessary for
substrates at monoamine transporters, such as MDMA and 4-MMC, to fully substitute in male rats.
As mentioned, four of eight subjects in the 0.3 mg/kg MDPV group displayed complete
generalization when tested with 3 mg/kg (+)-fenfluramine. Schechter and Rosecrans (1973) reported that
fenfluramine failed to fully substitute for a 10 mg/kg d-amphetamine cue in rats. Similarly, Goudie (1977)
reported that in female rats trained to discriminate 3 mg/kg fenfluramine from saline, d-amphetamine failed
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to fully substitute for the fenfluramine cue. In addition, a later study including human volunteers who were
trained to discriminate 10 mg d-amphetamine from placebo observed that 20 and 40 mg fenfluramine failed
to fully substitute for the d-amphetamine cue (Chait, Uhlenhuth, & Johanson, 1986). These findings
suggest that the dopamine releasing effects of amphetamine produce interoceptive cues that are dissimilar
from fenfluramine’s interoceptive cues (also see White & Appel, 1981). Later studies revealed that
fenfluramine’s interoceptive cues are likely mediated by serotonergic, as opposed to dopaminergic,
mechanisms. For example, McElroy and Feldman (1984) reported that in rats trained to discriminate 3
mg/kg fenfluramine from saline, p-chloroamphetamine, p-fluroamphetamine, and norfenfluramine fully
substituted for the fenfluramine cue. Contrariwise, fluoxetine, methysergide, cinanserin, chlordiazepoxide,
and 5-hydroxytryptophan failed to fully substitute for the fenfluramine cue, although 5-hydroxytryptophan
produced 56% drug-appropriate responding. Also relevant to the present study, McElroy and Feldman
(1984) observed that the (+)-fenfluramine isomer more potently substituted for the fenfluramine cue than
the (-)-fenfluramine isomer, suggesting that the former isomer more potently affects serotonergic
mechanisms, an effect consistent with previous in vitro experiments (e.g., Buczko, De Gaetano, &
Garattini, 1975). Finally, McCreary, Filip, and Cunningham (2003) reported that in rats trained to
discriminate 1 mg/kg fenfluramine from saline, a 5-HT2C/1B receptor agonist (mCPP) and a 5-HT2C receptor
agonist (MK 212) fully substituted for the fenfluramine cue. Moreover, a 5-HT2C receptor antagonist, SB
206553, dose-dependently reduced drug-appropriate responding. The results of that report suggest that the
stimulation of the 5-HT2C receptor elicits the 1 mg/kg fenfluramine cue. Considered together, the foregoing
studies implicate the role of serotonergic mechanisms in mediating fenfluramine’s discriminative cue.
Given that MDPV produces increases in extracellular levels of dopamine and norepinephrine, with
comparatively weaker effects on serotonin (e.g., Baumann et al., 2013), it is surprising that 3 mg/kg
fenfluramine fully substituted for 0.3 mg/kg MDPV in half the subjects. It is presently unknown if MDPV’s
discriminative effects (including downstream effects) are mediated by stimulation of serotonergic
mechanisms, although a recent report revealed that the rewarding and locomotor-stimulant effects of
cocaine (a drug with pharmacological actions similar to MDPV) are attenuated by 5-HT2C receptor
stimulation (Craige & Unterwald, 2013). Thus, it is possible that the interoceptive effects of MDPV may
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involve serotonergic mechanisms. Further drug discrimination research including drugs with selective
actions on serotonergic targets is warranted to evaluate this possibility.
An additional explanation for the unexpected substitution profile of (+)-fenfluramine may be the
subjects’ extensive drug and training histories by the time this drug was assessed for substitution. Drugs
with variable pharmacological effects were used in the present study to provide a comprehensive
substitution profile of MDPV. Although high doses of the substitution test compounds were avoided to
prevent potential neurotoxicity, it is possible that the subjects’ drug history influenced substitution test
results. It is noteworthy that (+)-fenfluramine, in particular, was the last tested drug in the present study.
Baker and Makhay (1996) demonstrated that (+)-fenfluramine injections altered the substitution profile in
1.5 mg/kg MDMA-trained rats, supporting the notion that the drug discrimination assay is sensitive to
intermittent drug-dosing regimens. In contrast, previous research has demonstrated that a subject’s drug
training history may not affect drug stimulus control in the context of phenobarbital discrimination in
pigeons, although phenobarbital stimulus control may weaken in the absence of training (e.g., McMillan,
Sun, & Hardwick, 1996). However, it is presently uncertain if psychostimulant stimulus control decays
following extended exposure to drugs of different pharmacological classes. It is therefore possible, though
presently unknown, if the drug history of 0.3 mg/kg MDPV-trained rats altered sensitivity to the stimulus
effects of compounds tested later in this study. Assessment of the impact of drug history on generalization
gradients using drug discrimination procedures may be a viable research pursuit.
Only one published study has trained rats to discriminate the interoceptive effects of 4-MMC from
saline. Varner et al. (2013) trained male Long-Evans hooded rats to discriminate 3.2 mg/kg 4-MMC from
saline under an FR 20 schedule of food reinforcement. In that study, only 3.2 mg/kg 4-MMC and 3.2 mg/kg
MDMA produced full substitution. Although ED50 values were not provided for 4-MMC and MDMA by
Varner et al., visual inspection of dose response curves in their report indicates possible ED 50 values for
4-MMC of ~1.0 mg/kg and for MDMA ~1.5 mg/kg (present study ED 50 values: 4-MMC = 0.18 mg/kg;
MDMA = 0.16 mg/kg) . Thus, as expected, the 1 mg/kg 4-MMC-trained rats in the present study appear
more sensitive to the interoceptive effects of these substances compared to those rats trained to discriminate
3.2 mg/kg 4-MMC in the Varner et al. study. In addition, Varner et al. reported that 18 mg/kg cocaine and
1.0 mg/kg methamphetamine, approached full substitution with 75.86%- and 72.86% 4-MMC-lever
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selection, respectively, whereas higher doses produced reductions in percent 4-MMC-lever responding. In
the present study, 1 mg/kg 4-MMC, 1 mg/kg MDMA, 3 mg/kg (+)-methamphetamine (n = 3), and 10
mg/kg (-)-cocaine produced full substitution in 4-MMC-trained rats. Notwithstanding the procedural and
rat strain differences between the present study and that by Varner et al., the training dose of 4-MMC is
likely to play a major role in the generalization gradients. In the study by Varner et al., relatively higher
doses of DA releasers approached full substitution before producing behavioral disruption. Similar findings
have been observed in 3 mg/kg 4-MMC-trained rats (Berquist, Thompson, & Baker, unpublished
observations). Contrariwise, it seems as though the 1 mg/kg 4-MMC-trained rats in the present study are
comparatively less sensitive to the disruptive effects of DA releasers, although (+)-methamphetamine only
fully substituted in three out of eight subjects.
It is likely that differences in substitution profiles obtained in the present study and that of Varner
et al. (2013) are due to different 4-MMC training doses. However, other procedural differences should also
be noted between these studies. The present study assessed substitution under extinction, with individual
test doses assessed on separate occasions. Varner et al. (2013) used cumulative-dosing procedures and
responses were reinforced during test sessions. In one study, Kaempf and Kallman (1987) trained rats to
discriminate 3 mg/kg morphine from saline, and then tested the training drug on two occasions (1-5 mg/kg
morphine) for stimulus substitution under 4-min reinforced and non-reinforced conditions. Kaempf and
Kallman reported statistical differences in the generalization gradients between the reinforced and
non-reinforced conditions. It is worth noting that Kaempf and Kallman did not end the session after a
subject completed first FR 32 during the testing conditions; rather, a subject was permitted to respond (and
receive reinforcers in the reinforced condition) for the entire 4-min session. Unfortunately, there are
currently no known published studies that have directly compared reinforced test sessions to extinction test
sessions and ended the test session following completion of the first response requirement. Without direct
comparisons of reinforced and extinction sessions ending after the first response in the same study, it
remains undetermined whether reinforced test sessions produce changes in generalization gradients
obtained using DD procedures.
As a final point, it is worth noting that although direct comparisons between substitution profiles
generated from 0.3 mg/kg MDPV- and 1 mg/kg 4-MMC-trained rats was not the purpose of the present
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study, drug-lever selection by subjects that displayed high percent substitution values for some test
compound in one training group was moderately correlated (except for MDMA) with drug-lever selection
by subjects in the other training group (see Figure 12). As such, these findings support previous reports
indicating that MDPV and 4-MMC can produce comparable subjective effects in humans (e.g., Ross,
Reisfield, Watson, Chronister, & Goldberger, 2012). Moreover, to further characterize the interoceptive
effects produced by MDPV and 4-MMC, future studies should include different training doses of the drugs,
and blockade tests with drugs possessing selective receptor affinities to determine the neural mechanisms
involved in mediating their discriminative cues.
The DD assay serves as a highly valuable investigative tool in behavioral pharmacology and
neurobiological research. Numerous studies have demonstrated that nonhuman subjects and human
volunteers trained to discriminate a dose of a drug from vehicle, doses of the same drug, doses of other
drugs, or drug mixtures are sensitive to the effects of test drugs with comparable interoceptive effects.
Moreover, rigorous investigations into neural mechanisms responsible for mediating such effects serves as
one of the DD paradigm’s most appealing qualities, especially because such experimentation is often
precluded in human volunteers. The research included herein serves to perpetuate the utility of the DD
model as a predictive and useful drug-detection assay.
Conclusion
Synthetic cathinones are currently an international public health concern given their untoward
effects on personal and social harm measures. Through continued scientific investigations of their
behavioral and neurochemical effects, we can better understand their abuse potential and eventually
develop treatment strategies for users who consume these drugs to excess. Toward this goal,
characterization of the psychopharmacology of synthetic cathinones remains a socially-relevant scientific
endeavor. The research included herein serves as one step toward achieving that goal.
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Table 1
Individual Subject Performances for MDPV Substitution Tests and Response Rates in 0.3 mg/kg
MDPV-trained Rats
Percent MDPV-Lever Selection
Subjects
Dose (mg/kg)

G1

G2

G3

0
0.01
0.03
0.1
0.3

100
0
27.59
100
100

0
0
19.23
100
100

Dose (mg/kg)

G1

G2

G3

0
0.01
0.03
0.1
0.3

1.35
2.86
2.25
1.32
1.60

1.96
6.06
1.60
1.94
2.08

2.94
2.44
2.82
1.79
2.17

G4

G5

G6

G7

G8

18.18
12.5
12.5
0
100

0
0
0
57.41
100

0
0
8
29.41
100

26.67
0
0
47.92
100

G4

G5

G6

G7

G8

0.95
1.54
1.67
1.65
0.41

1.23
1.67
1.21
1.20
0.91

2.38
2.67
2.22
2.23
1.85

1.89
1.72
2.41
1.66
1.92

1.18
1.80
1.07
1.75
1.79

0
0
100
0
100
0
100
0
100
100
Response Rate
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Table 2
Individual Subject Performances for 4-MMC Substitution Tests and Response Rates in 0.3 mg/kg
MDPV- trained Rats
Percent MDPV-Lever Selection
Subjects
Dose (mg/kg)

G1

G2

0.03
0
24.14
0.1
43.24
8.70
0.3
0
8.70
1
100
4.55
3
16
100
10
DNC
100
DNC = did not complete FR 20

G3

G4

G5

G6

G7

G8

0
0
0
100
4.55
20.45

0
0
8.33
0
67.31
DNC

6.62
4.55
0
22.22
100
100

4.55
0
8.70
0
100
95.65

0
0
0
0
100
69.70

22.22
0
44.44
100
84.62
77.78

Response Rate
Dose (mg/kg)

G1

G2

G3

G4

G5

G6

G7

G8

0.03
0.1
0.3
1
3
10

1.72
1.65
1.39
0.93
0.20
0.00

1.56
3.03
3.77
3.73
1.10
0.08

2.86
2.06
1.25
1.90
1.38
0.04

0.75
2.30
0.93
1.16
0.16
0.00

1.29
1.11
0.63
0.64
0.25
0.03

1.80
2.86
2.07
1.80
0.20
0.02

2.50
1.83
1.87
1.96
0.88
0.04

1.28
0.85
0.89
0.40
0.20
0.04
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Table 3
Individual Subject Performances for d-Amphetamine Substitution Tests and Response Rate in 0.3 mg/kg
MDPV-trained Rats
Percent MDPV-Lever Selection
Subjects
Dose (mg/kg)

G1

G2

0
0.03
0.1
0.3
1

0
0
100
100
100

4.55
0
12.5
100
100

G3

G4

4.55
8.33
0
0
12
4.17
43.90
95.24
100
100
Response Rate

G5

G6

G7

G8

41.67
4.55
29.03
4.55
100

4.55
0
0
100
100

0
0
0
100
100

32.26
50
100
100
100

Dose (mg/kg)

G1

G2

G3

G4

G5

G6

G7

G8

0
0.03
0.1
0.3
1

2.33
1.54
1.61
2.30
2.50

2.72
7.14
4.07
2.25
1.80

1.49
2.53
1.16
0.90
1.43

1.85
3.70
1.74
1.08
0.85

1.34
1.30
1.38
1.09
0.94

2.34
2.63
2.04
2.06
2.20

2.33
1.61
2.50
2.06
1.87

1.86
1.63
1.09
1.32
1.75
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Table 4
Individual Subject Performances for (+)-Methamphetamine Substitution Tests and Response Rates in 0.3
mg/kg MDPV-trained Rats
Percent MDPV-Lever Selection
Subjects
Dose (mg/kg)

G1

G2

G3

0.03
0.1
0.3
1

100
43.24
8.70
100

0
100
100
100

Dose (mg/kg)

G1

0.03
0.1
0.3
1

2.17
1.95
2.19
1.90

G4

G5

G6

G7

G8

0
4.55
0
96
100
92
100
82.86
Response Rate

8.70
8.70
100
100

0
0
100
100

0
0
100
100

0
0
94.29
100

G2

G3

G4

G5

G6

G7

G8

6.45
3.03
3.70
2.70

2.53
2.15
0.77
1.20

2.34
1.14
0.83
0.77

1.50
1.00
1.98
2.06

2.53
2.11
1.69
1.45

1.57
1.57
1.12
1.82

1.87
1.82
0.99
2.86
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Table 5
Individual Subject Performances for (-)-Cocaine Substitution Tests and Response Rates in 0.3 mg/kg
MDPV-trained Rats
Percent MDPV-Lever Selection
Subjects
Dose (mg/kg)

G1

G2

G3

0.1
0.3
1
3
10

0
100
100
44.74
100

0
100
100
0
100

Dose (mg/kg)

G1

0.1
0.3
1
3
10

3.28
1.68
0.92
1.50
2.30

G4

G5

G6

G7

G8

0
0
0
4.55
7.69
0
100
3.45
100
83.33
Response Rate

8.70
4.55
100
100
100

40.38
51.28
4.55
100
100

0
0
100
100
100

0
0
100
95.65
100

G2

G3

G4

G5

G6

G7

G8

3.85
4.08
2.33
5.71
2.78

1.97
1.75
1.07
2.06
1.20

1.71
3.38
1.90
1.26
1.55

1.49
1.39
1.57
1.69
2.13

2.30
1.92
1.83
1.89
1.83

1.12
1.65
2.35
1.71
1.36

2.67
1.85
0.56
0.77
2.56
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Table 6
Individual Subject Performances for MDMA Substitution Tests and Response Rates in 0.3 mg/kg
MDPV-trained Rats
Percent MDPV-Lever Selection
Subjects
Dose (mg/kg)

G1

0
0
0.1
100
0.3
0
1
0
3
36.36
DNC = did not complete FR 20

G2

G3

G4

G5

G6

G7

G8

0
0
4.55
5.41
0

0
0
0
0
0

10.87
0
4.55
0
50

59.26
35.29
18.52
100
100

0
0
0
0
0

0
0
34.38
12.5
0

0
0
4.55
100
DNC

Response Rate
Dose (mg/kg)

G1

G2

G3

G4

G5

G6

G7

G8

0
0.1
0.3
1
3

3.17
1.54
2.22
1.30
0.67

7.14
5.26
3.44
1.34
1.85

2.56
1.92
2.82
2.25
0.73

0.67
1.82
1.47
2.11
0.13

2.50
1.81
2.11
0.98
0.71

1.96
1.55
1.67
2.38
1.44

1.34
1.79
1.43
1.50
1.26

1.60
1.42
0.81
1.06
0
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Table 7
Individual Subject Performances for (+)-LSD Substitution Tests and Response Rates in 0.3 mg/kg
MDPV-trained Rats
Percent MDPV-Lever Selection
Subjects
Dose (mg/kg)

G1

0.01
0
0.03
100
0.1
0
DNC = did not complete FR 20

G2

G3

G4

G5

G6

G7

G8

0
0
0

0
4.55
58.33

0
0
DNC

16
8.70
100

0
0
43.24

26.67
0
0

95.24
0
0

Response Rate
Dose (mg/kg)

G1

G2

G3

G4

G5

G6

G7

G8

0.01
0.03
0.1

2.44
1.19
1.74

3.57
2.78
4.00

0.95
1.25
0.73

3.13
0.66
0.00

1.80
1.85
1.04

2.25
2.94
1.46

1.62
1.69
0.67

0.07
1.14
0.41
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Table 8
Individual Subject Performances for (+)-Fenfluramine Substitution Tests and Response Rates in 0.3 mg/kg
MDPV-trained Rats
Percent MDPV-Lever Selection
Subjects
Dose (mg/kg)

G1

0.03
27.59
0.1
73.53
0.3
0
1
0
3
59.52
DNC = did not complete FR 20

G2

G3

G4

G5

G6

G7

G8

0
0
47.62
68.75
100

0
0
0
0
DNC

0
0
0
28.43
DNC

100
100
33.82
67.74
100

7.32
0
0
0
100

0
0
0
60.61
DNC

0
0
100
0
DNC

Response Rate
Dose (mg/kg)

G1

G2

G3

G4

G5

G6

G7

G8

0.03
0.1
0.3
1
3

0.81
0.31
1.29
0.71
0.06

1.23
1.83
1.85
1.93
0.74

2.15
1.28
1.2
1.23
0

0.40
1.85
0.84
0.19
0

0.09
0.72
1.30
0.82
1.03

0.11
1.08
2.08
2.56
1.36

2.04
1.39
2.50
1.20
0

1.14
1.26
1.03
1.35
0
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Individual Subject Substitution Test and Response Rate Results in 1.0 mg/kg 4-MMC Training
Group
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Table 1
Individual Subject Performances for 4-MMC Substitution Tests and Response Rates in 1.0 mg/kg
4-MMC- trained Rats
Percent 4-MMC-Lever Selection
Subjects
Dose (mg/kg)

R1

R2

R3

0
0.01
0.03
0.1
0.3
1

31.25
0
31.11
7.69
0
100

0
0
100
0
100
95.24

Dose (mg/kg)

R1

R2

R3

0
0.01
0.03
0.1
0.3
1

1.67
1.96
1.76
1.68
1.80
1.92

3.33
3.77
3.39
2.90
2.78
2.23

1.38
1.69
0.98
1.28
1.69
1.67

R4

R5

R6

R7

R8

0
0
100
74.07
100
100

0
0
46.15
0
0
90.91

0
0
0
4
0
83.33

0
0
0
16
0
100

R4

R5

R6

R7

R8

1.77
1.58
1.51
2.38
2.63
1.94

2.20
2.13
1.63
2.29
1.64
1.90

2.15
2.06
2.20
1.55
1.44
1.35

2.56
2.53
2.27
2.17
2.47
1.03

0.36
1.22
0.89
1.60
1.72
2

8.70
8.70
100
4.55
0
4.55
100
16
100
100
100
100
Response Rate

95

Table 2
Individual Subject Performances for MDMA Substitution Tests and Response Rates in 1.0 mg/kg
4-MMC-trained Rats
Percent 4-MMC-Lever Selection
Subjects
Dose (mg/kg)

R1

R2

R3

0
0.03
0.1
0.3
1

0
0
0
0
100

100
0
0
0
100

R4

0
0
0
0
100
19.23
46.15
0
100
84.62
Response Rate

R5

R6

R7

R8

0
0
0
0
100

0
0
0
0
90.91

0
0
0
95.24
95.24

4.55
12.5
40
100
100

Dose (mg/kg)

R1

R2

R3

R4

R5

R6

R7

R8

0
0.03
0.1
0.3
1

2.22
1.89
1.98
1.79
1.64

0.62
4.00
2.86
4.65
1.36

1.05
1.00
1.38
0.66
1.27

1.71
2.86
1.26
2.22
1.52

2.08
1.92
2.53
1.64
1.44

2.30
1.48
2.44
2.60
0.79

1.69
3.02
2.78
1.50
2.00

1.72
1.52
1.67
1.41
1.92
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Table 3
Individual Subject Performances for (+)-LSD Substitution Tests and Response Rates in 1.0 mg/kg
4-MMC-trained Rats
Percent 4-MMC-Lever Selection
Subjects
Dose
(mg/kg)

R1

R2

0.01
0
0
0.03
0
100
0.1
0
DNC
0.2
DNC
DNC
DNC = did not complete FR 20

R3

R4

R5

R6

R7

R8

8.70
86.21
4.55
DNC

4.55
0
100
DNC

0
0
44.74
35.29

0
0
40.91
29.03

4.55
0
62.03
DNC

0
0
92.31
DNC

Response Rate
Dose (mg/kg)

R1

R2

R3

R4

R5

R6

R7

R8

0.01
0.03
0.1
0.2

2.08
2.11
0.57
0

5
1.96
0
0

0.84
1.05
0.85
0

2.37
2.11
0.80
0

2.56
1.64
0.61
0.08

2.33
1.41
0.22
0.07

1.46
1.68
0.09
0

1.09
1.48
0.05
0
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Table 4
Individual Subject Performances for (+)-Fenfluramine Substitution Tests and Response Rates in 1.0 mg/kg
4-MMC-trained Rats
Percent 4-MMC-Lever Selection
Subjects
Dose (mg/kg)

R1

R2

0.1
0
100
0.3
0
0
1
0
23.4
3
25.49
DNC
DNC = did not complete FR 20

R3

R4

R5

R6

R7

R8

12.5
0
88.89
DNC

41.67
0
4.55
100

DNC
0
100
96.88

0
41.67
95.24
48.53

0
46.67
100
97.56

28.81
100
46.15
100

Response Rate
Dose (mg/kg)

R1

R2

R3

R4

R5

R6

R7

R8

0.1
0.3
1
3

2.78
2.33
0.94
0.16

0.75
0.68
0.47
0

1.36
1.33
0.66
0

1.55
1.01
1.36
0.36

0
0.43
0.75
0.09

2.13
0.91
1.14
1.05

2.67
0.75
0.96
1.02

1.09
0.89
0.73
0.07
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Table 5
Individual Subject Performances for MDPV Substitution Tests and Response Rates in 1.0 mg/kg
4-MMC-trained Rats
Percent 4-MMC-Lever Selection
Subjects
Dose (mg/kg)

R1

0.03
0
0.1
0
0.3
0
1
0
3
DNC
DNC = did not complete FR 20

R2

R3

R4

R5

R6

R7

R8

0
0
0
0
4.55

0
19.23
8.70
75
100

8.7
100
8.70
59.46
91.30

0
0
100
95.24
100

0
0
0
95.24
100

8.70
0
0
95.24
100

4.55
12.5
8.70
85.19
100

Response Rate
Dose (mg/kg)

R1

R2

R3

R4

R5

R6

R7

R8

0.03
0.1
0.3
1
3

1.12
2.25
1.47
0.17
0

3.28
2.02
1.16
0.19
0.10

0.99
0.64
1.16
1.46
1.02

0.96
1.67
1.72
1.32
2.56

2.20
1.61
1.47
0.50
0.33

2.41
2.67
1.69
0.94
1.59

1.78
1.98
2.17
0.06
0.28

1.38
1.24
1.36
0.9
1.28
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Table 6
Individual Subject Performances for d-Amphetamine Substitution Tests and Response Rates in 1.0 mg/kg
4-MMC-trained Rats
Percent 4-MMC-Lever Selection
Subjects
Dose (mg/kg)

R1

R2

R3

0
0.03
0.1
0.3
1

0
0
0
62.86
95.24

0
0
0
0
100

Dose (mg/kg)

R1

R2

R3

0
0.03
0.1
0.3
1

1.23
2.35
1.83
0.60
0.39

4.17
4.83
4
4.55
0.34

1.56
1.05
0.91
0.70
0.98

R4

R5

R6

R7

R8

100
0
0
0
0

0
0
69.33
95.24
59.42

22.22
0
0
53.85
100

25
4.55
0
22.22
100

R4

R5

R6

R7

R8

1.13
1.48
1.55
0.84
0.34

2.82
1.69
2
3.85
1.61

2.08
2.67
1.23
0.89
1.06

2.27
1.79
1.6
1.76
1.37

1.56
1.64
1.25
0.6
1.69

100
16
38.24
4.55
8
16
0
32.26
100
97.06
Response Rate
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Table 7
Individual Subject Performances for (+)-Methamphetamine Substitution Tests and Response Rates in 1.0
mg/kg 4-MMC-trained Rats
Percent MDPV-Lever Selection
Subjects
Dose (mg/kg)

R1

0.03
0
0.1
100
0.3
5.41
1
95.24
3
DNC
DNC = did not complete FR 20

R2

R3

R4

R5

R6

R7

R8

0
0
58.82
100
DNC

4.55
90.91
100
100
DNC

4.55
100
94.29
100
DNC

0
100
0
0
DNC

0
0
8
0
100

0
0
0
86.96
100

4.55
100
100
100
100

Response Rate
Dose (mg/kg)

R1

R2

R3

R4

R5

R6

R7

R8

0.03
0.1
0.3
1
3

1.57
1.59
1.51
1.45
0

1.79
3.85
2.96
2.86
0

0.89
2.68
1.32
1.39
0

1.51
0.83
2.61
0.82
0

1.77
1.74
2.70
1.65
0

2.94
2.04
1.67
1.80
0.97

1.57
2.22
1.41
1.40
0.19

1.13
1.02
1.05
1.48
1.01
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Table 8
Individual Subject Performances for (-)-Cocaine Substitution Tests and Response Rates in 1.0 mg/kg
4-MMC-trained Rats
Percent 4-MMC-Lever Selection
Subjects
Dose (mg/kg)

R1

R2

R3

0
0.03
0.1
1
3
10

0
16.00
0
95.24
95.24
100

0
0
95.24
0
0
100

Dose (mg/kg)

R1

R2

R3

0
0.03
0.1
1
3
10

1.79
1.21
1.92
1.98
0.49
1.82

3.70
2.20
2.63
4.65
1.23
0.41

0.69
0.91
1.03
1.54
2.02
1.74

R4

R5

R6

R7

R8

0
0
0
42.11
100
100

0
0
0
95.24
0
95.24

95.24
0
0
97.44
100
100

4.00
0
12.50
13.79
100
89.47

R4

R5

R6

R7

R8

0.82
0.65
1.14
1.96
1.90
1.03

2.62
1.98
2.08
1.77
0.86
0.12

2.13
1.54
2.44
1.15
2.35
1.64

1.27
2.30
2.35
2.13
2.11
2.02

1.79
0.93
1.58
1.41
1.18
1.07

8.70
0
4.00
0
100
0
100
4.55
88.00
0
100
100
Response Rate
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